

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 860 447 A1

(12)

EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

(43) Date of publication:
26.08.1998 Bulletin 1998/35

(51) Int. Cl.⁶: C07K 14/52, C07K 16/24,
C12N 15/19, C12N 1/21,
C12N 5/18, C12N 5/20,
C12P 21/02, C12P 21/08,
A61K 38/17

(21) Application number: 97937809.8

(86) International application number:
PCT/JP97/02985

(22) Date of filing: 27.08.1997

(87) International publication number:
WO 98/08869 (05.03.1998 Gazette 1998/09)

(84) Designated Contracting States:
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE

(72) Inventors:
• HIRAOKA, Atsunobu,
27-34, Kitachuin-cho
Kyoto 616 (JP)
• SUGIMURA, Atsushi,
4-6, Yamate-cho 4-chome
Hokkaido 061-11 (JP)
• MIO, Hiroyuki,
1-1-102, Miyanosato 1-chome
Kanagawa 243-02 (JP)

(30) Priority: 27.08.1996 JP 262252/96
24.03.1997 JP 87242/97
07.07.1997 WO PCT/JP97/02349

(74) Representative:
Maschlo, Antonio et al
D Young & Co,
21 New Fetter Lane
London EC4A 1DA (GB)

(71) Applicants:
• KYOWA HAKKO KOGYO CO., LTD.
Chiyoda-ku, Tokyo 100-8185 (JP)
• Hiraoka, Atsunobu
Kyoto-shi, Kyoto 616 (JP)

(54) HEMATOPOIETIC STEM CELL GROWTH FACTOR (SCGF)

(57) A novel polypeptide exhibiting a growth promoting activity on hematopoietic stem cells; a gene encoding this polypeptide; an antibody reacting specifically with the polypeptide; a process for isolating the above-mentioned gene; and a vector to be used in this process. Thus, the pathologies of various hemopoietic organ diseases caused by abnormalities in hematopoietic cells and bone marrow inhibition can be clarified and, in its turn, these diseases can be diagnosed or treated. Also, it becomes possible to amplify hematopoietic cells *in vitro* for marrow graft required in treating these diseases or to elevate the gene transfer efficiency into hematopoietic stem cells for gene utilization. Moreover, the above-mentioned process and vector for isolating the SCGF gene are applicable to the clarification of other novel genes and thus contribute to the development of genetic engineering techniques.

EP 0 860 447 A1

Description**Technical Field of the Invention**

5 The present invention relates to a novel hematopoietic growth factor protein termed hematopoietic stem cell growth factor (hereinafter referred to as "SCGF") which acts on hematopoietic stem cells to maintain their survival and to induce their proliferation and differentiation. The present invention also relates to a gene coding for SCGF; a vector comprising the gene; a transformant transformed with the vector; a method for producing SCGF; and a method for separating and purifying SCGF. The present invention further relates to the use of SCGF as a therapeutic for hematopoietic
 10 insufficiency derived from irradiation or chemotherapy for patients with various hematopoietic diseases or cancers; or the use of SCGF as a reagent for diagnostic analysis. The present invention also relates to the use of SCGF in bone marrow transplantation for the purpose of hematopoietic recovery, for which hematopoietic stem cells can be amplified with SCGF *in vitro* in a small amount of bone marrow aspirates; and the use of SCGF in gene therapy to improve the efficiency of a gene transfer into hematopoietic stem cells. The invention also relates to a vector developed to isolate
 15 the SCGF gene, as well as a method for isolating the gene. The vector and the method can provide promising tools to search for other novel genes for unknown proteins.

Technical Background of the Invention

20 Hematopoiesis in the bone marrow is regulated by direct interaction between (i) self-renewable hematopoietic stem cells, hematopoietic progenitor cells derived therefrom and committed to respective differentiation pathways and cell populations at consecutive differentiation stages between the above two types of cells, and (ii) stromal cells as hematopoietic inductive microenvironment supporting the above cells, or by indirect interaction between (i) cells and hematopoietic humoral factors secreted by (ii) cells. A number of hematopoietic humoral factors are also secreted by
 25 extramedullary organs such as the kidney or the liver. Peripheral blood cells with a limited life span are continuously recruited through the hematopoietic network spreading over the whole body which results in maintaining the haemopoietic stasis. The complicated hematopoietic mechanisms have been analyzed using the following two approaches; first, the process of hematopoietic recovery from myelosuppression is studied *in vivo* in the experimental animals such as mouse, dog or sheep, which are irradiated or given cytotoxic reagents such as 5-fluorouracil. Second, interaction
 30 between hematopoietic stem cells and stromal cells or humoral factors is studied *in vitro*, using a clonal culture of the human and mammalian bone marrow cells.

With the progress in molecular biology, a number of genes for cytokines including hematopoietic growth factors have been successfully cloned. Such cytokines include erythropoietin (hereinafter referred to as "Epo"), thrombopoietin, colony stimulating factors such as granulocyte colony-stimulating factor (hereinafter referred to as "G-CSF"), macrophage colony-stimulating factor (hereinafter referred to as "M-CSF"), granulocyte macrophage colony-stimulating factor (hereinafter referred to as "GM-CSF") interleukins such as IL-1, IL-3, IL-4, IL-5, IL-6, IL-9, IL-11 and IL-12 recently identified stem cell factor (SCF) and flk-2/flt3 ligand (Lin et al., Proc. Natl. Acad. Sci. USA 82, 7580-7584, 1985; de Sauvage et al., Nature 369, 533-538, 1994; Nagata et al., EMBO J. 5, 575-581, 1986; Wong et al., Science 235, 1504-1508, 1987; Miyatake et al., EMBO J. 4, 2561-2568, 1985; Clark et al., Nucleic Acids Res. 14, 7897-7914, 1986; Dorssers et al., Gene 55, 115-124, 1987; Yokota et al., Proc. Natl. Acad. Sci. USA 83, 5894-5898, 1986; Campbell et al., Proc. Natl. Acad. Sci. USA 84, 6629-6633, 1987; Yasukawa et al., EMBO J. 6, 2939-2945, 1987; Yang et al., Blood 74, 1880-1884, 1989; Paul et al., Proc. Natl. Acad. Sci. USA 87, 7512-7516, 1990; Wolf et al., J. Immunol. 146, 3074-3081, 1991; Anderson et al., Cell 63, 235-243, 1990; Lyman et al., Cell 75, 1157-1167, 1993). These cytokines have been well characterized biologically and biochemically, and their industrial production has become possible. G-CSF, M-CSF and Epo are used clinically as recombinant preparations for hematopoietic insufficiency derived from irradiation or chemotherapy and anemia associated with renal failure, respectively. However, when hematopoietic insufficiency due to quantitative or qualitative hematopoietic stem cell abnormalities is treated with the recombinant hematopoietic growth factors, peripheral blood counts are only transiently improved. Hematopoietic insufficiency often recurs with cessation of the hematopoietic growth factors. In other words, presently available hematopoietic growth factors have not achieved radical cure of hematopoietic insufficiency due to hematopoietic stem cell abnormalities.

Auto- or allo-graft of bone marrow, peripheral blood and cord blood hematopoietic stem cells are common procedures for hematopoietic insufficiency. On the other hand, hematopoietic stem cells in the bone marrow, peripheral blood or cord blood cells are tried to be amplified *in vitro* with hematopoietic growth factors and then transplanted. Among the factors described above, SCF, IL-3, G-CSF and IL-6 play a major role in amplification of hematopoietic stem cells and immature progenitors. These factors are known to exhibit the so-called "synergistic effect", i.e. they induce higher amplification when used in combination than when used alone. Mouse hematopoietic stem cells can be amplified *in vitro* to 10-fold and progenitor cells to 1000-fold in response to the hematopoietic growth factors. In human, however, an expected amplification effect has not been achieved with the combination of SCF, IL-3, G-CSF and IL-6 that is effec-

tive in the mouse system (Bernstein et al., *Blood* **77**, 2316-2321, 1991; Brandt et al., *Blood* **79**, 634-641, 1992; Srour et al. *Blood* **81**, 661-669, 1993). This not only implies that human cells expressing the receptors for the hematopoietic growth factors are different from mouse ones, but strongly suggests the existence of unknown factors involved in human hematopoiesis.

When host cells are transfected or infected, in gene therapy, with a retrovirus vector carrying a normal gene or a gene of interest, the efficiency of gene transfer will be extremely low if the host cells are not in the cell cycle and, as a result, no expression of the gene can be achieved. If a gene is transferred into the short-lived mature blood cells, gene therapy should be repeated many times since the expression of the gene is transient. Therefore, hematopoietic stem cells are a preferable target for gene transfer, for the reason that it is therapeutically excellent to transfer a gene of interest into hematopoietic stem cells once to thereby supply cells expressing the gene permanently. However, since hematopoietic stem cells are usually quiescent in the G₀ phase, attempts have been made to enter them into the cell cycle using a combination of hematopoietic growth factors such as SCF, IL-3, G-CSF, IL-6 and so forth. The efficiency of gene-transfer is still as low as 40%, which is the biggest problem in gene therapy (Nolta et al., *Hum. Gene Therapy* **1**, 257-268, 1990; Stoeckert et al., *Exp. Hematol.* **18**, 1164-1170, 1990; Dick et al., *Blood* **78**, 624-634, 1991; Cournoyer et al., *Hum. Gene Therapy* **2**, 203-213, 1991; Hughes et al., *J. Clin. Invest.* **89**, 1817-1824, 1992).

Hiraoka et al. have found a growth activity on human hematopoietic stem cells in the culture supernatant of normal human peripheral blood mononuclear cells and that of undifferentiated myeloid KPB-M15 cells established from the peripheral blood leukocytes of the patient with chronic myelogenous leukemia in blast crisis, designated the activity "hematopoietic stem cell growth factor" (SCGF) and tried to purify the factor (Hiraoka et al., *Cell Biol. Int. Rep.* **10**, 347-355, 1986; Hiraoka et al., *Cancer Res.* **47**, 5025-5030, 1987). The hematopoietic activities of SCGF include, erythroid burst-promoting activity (hereinafter referred to as "BPA") in the presence of Epo and granulocyte macrophage colony-promoting activity (hereinafter referred to as "GPA") in the presence of GM-CSF on human bone marrow cells, while SCGF lacks colony-stimulating activity (hereinafter referred to as "CSA").

Since human SCGF shows a strict species-specificity, i.e. it is active on human hematopoietic stem or progenitor cells but not on mouse cells, investigators should not use mouse bone marrow cells but human cells for purification and identification of SCGF. Human bone marrow cells are least available due to the limited number of donors, so the progress in the studies is limited and it has been remained ambiguous whether SCGF is different from or identical with a known factor.

30 Problem for Solution by the Invention

It is an object of the invention to identify the molecular characteristics of the novel hematopoietic growth factor "SCGF" through purification of SCGF protein and cloning of a gene coding for SCGF, and to provide the recombinant SCGF preparation. The present invention intends to contribute to the *in vitro* amplification of human hematopoietic stem and progenitor cells, amelioration of various hematopoietic disorders, gene therapy and the diagnosis of diseases. In view of the species-specificity of SCGF, the present invention intends to make clear an important aspect of SCGF-concerned hematopoietic mechanisms unidentified expanded from the studies using mouse bone marrow cells.

Disclosure of the Invention

Since recombinant DNA technology has remarkably advanced, isolation and identification of a gene has become possible even for quite a small amount of a physiologically active protein (Huynh et al., *DNA Cloning I. A Practical Approach*, Glover (ed.), Oxford, Washington, IRL Press, 49-78, 1985; Sambrook, Fritsch and Maniatis, 1989, *Molecular Cloning. A Laboratory Manual*, 2nd Edition, Cold Springs Harbor Laboratory Press, 1989). There are two major methods for isolating a gene. First is a protein-purification leading method, to determination of the partial amino acid sequence; an optimal oligo-DNA probe is prepared based on the amino acid sequence, then a relevant gene is screened to hybridize with the DNA probe (i.e., a gene which is expected to encode the same amino acid sequence as that of the purified protein), from a large-scale cDNA library. Second is an expression cloning method; a protein is secreted by cells expressing a relevant cDNA clone and detected using an activity assay system or a specific antibody. The latter is superior to the former in that the protein need not be highly purified for isolation of the gene. It means the expression cloning method requires the specific antibody or sensitive activity assay system for successful gene isolation.

The present inventors have modified and improved the expression cloning method. First, the genes totally different from that for SCGF have been tried to be excluded from a cDNA library. Briefly, the positive DNA probes was prepared from DNA of SCGF-producing KPB-M15 cells subtracted with SCGF-infertile MOLT-4 cells, and the negative probe from DNA of the MOLT-4 cells. For a differential cloning, the genes that hybridize with the positive probe but not with the negative probe were sorted from a cDNA library of KPB-M15 cells. Somewhat less sensitive assay system for SCGF activity can be appropriate to detect SCGF cDNA clone by reducing the number of expression samples from the sorted

cDNA clones. While a cDNA should be ligated to a phage vector for differential hybridization, it be ligated to a plasmid vector for expression of the cDNA in mammalian cells to rest the SCGF activity of the protein. In order to meet the demand, the inventors have developed a novel vector convertible from a phage vector to a plasmid one on the same vector. Briefly, genes for replication in *E. coli* and expression in mammalian cells were ligated into a λ phage vector with a flanking replication initiator and terminator. The λ phage vector was packaged and coinfecting with a helper phage into *E. coli*, replicating to circularize the region between the initiator and terminator. The replicated circular DNA was covered with the coat protein to develop an infectious phagemid. When *E. coli* was infected with the phagemid, the circular DNA in the phagemid was transferred into the *E. coli*, resulting in transformation of *E. coli*. The DNA between replication initiator and terminator in the λ phage vector was consequently transferred into *E. coli* to be plasmid-like. Since the plasmid-like circular DNA had the ability to replicate in *E. coli* and to be expressed in mammalian cells, the initial λ phage vector had been converted to a plasmid vector without DNA recombination.

A KPB-M15 cDNA library was prepared into the above vector. About 60,000 cDNA clones were sorted to about 6,800 through differential cloning. Gene products expressed in COS cells were screened for BPA. cDNA clone No. 116-10C was isolated as that for SCGF. Nucleotide sequencing showed that the cDNA had 1,196 nucleotides with a long open reading frame that encoded a 245-amino acid polypeptide. About 20 amino acids at an N-terminal region were hydrophobic. No homology with the database in the EMBL and GenBank was found for the cDNA sequence in the total or most of the coding region, though only one short DNA fragment showed partially high homology with the 3' untranslated region of the cDNA clone No. 116-10C. Furthermore, no homology with database in the Swiss-Prot was found for the amino acid sequence. Collectively, cDNA clone No. 116-10C has been confirmed to be a gene coding for the novel hematopoietic growth factor SCGF. Thus, the present invention has been achieved.

Hereinbelow, the present invention will be described in detail.

First, the invention relates to a mammalian polypeptide with BPA or GPA on the bone marrow cells.

Secondly, the invention relates to a mammalian gene that encodes a polypeptide with BPA or GPA on the bone marrow cells.

Thirdly, the invention relates to a vector carrying the above gene.

Fourthly, the invention relates to a transformant transformed with the above vector.

Fifthly, the invention relates to a specific antibody for the above polypeptide.

Sixthly, the invention relates to microorganisms, animal cells or animals producing the above antibody.

Seventhly, the invention relates to a method for producing the above polypeptide by the culture cells possessing the above gene.

Eighthly, the invention relates to a method for purification of the above polypeptide using one or more of an anion exchange, a hydrophobic, a gel filtration, a pigment and lectin affinity, and a metal-chelating chromatography.

Ninthly, the invention relates to a pharmaceutical composition the above polypeptide as an active ingredient.

Tenthly, the invention relates to a λ phage vector which has at least 2 functional DNA regions for replication in *E. coli* and for expression in mammalian cells with a flanking replication initiator and a terminator from a filamentous phage.

Eleventhly, the invention relates to a method for isolating a gene using the above λ phage vector.

(1) The Polypeptide of the Invention (the 1st Invention)

The polypeptide of the invention is that of a mammalian origin possessing BPA or GPA on the bone marrow cells. BPA can be detected by erythroid bursts formation in a soft agar culture of the bone marrow cells in response to Epo and the polypeptide to be tested. For example, bone marrow cells are seeded at a density of 5×10^4 /ml into 0.3% agar medium, containing 1 unit/ml of Epo and the polypeptide. Erythroid bursts consisting of erythroblasts are enumerated under an inverted microscope after 14-day culture. GPA can be detected by an increase in the number of GM colonies formed in a soft agar culture of the bone marrow cells in response to GM-CSF and the polypeptide. For example, bone marrow cells are seeded at a density 5×10^4 /ml in 0.3% agar medium, containing 5 ng/ml of GM-CSF and the polypeptide. GM colonies consisting of granulocytes and macrophages are enumerated under an inverted microscope after 10-day culture. Bone marrow cells are aspirated from the mammalian sternum or ilium, and suspended in a medium, e.g. Iscove's modified Dulbecco's medium (IMDM) containing 10% fetal calf serum (FCS). Low density mononuclear cells are separated by centrifugation on a high density isotonic cushion, e.g. Ficoll.

The polypeptide of the invention can be obtained by the cultures of cells possessing the gene of the invention (the 2nd invention) described below.

Human placenta and KPB-M15 cells are candidates of cells possessing the gene of the invention. Cells with the recombinant gene of the invention are another sources.

Structure of the purified polypeptide of the invention can be analyzed by conventional methods used in protein chemistry, e.g. the method described in Hisashi Hirano, Structural Analysis of Proteins for Gene Cloning, Tokyo Kagaku Dojin Co., 1993.

In addition to the use as a pharmaceutical composition described below, the polypeptide of the invention can be used for auto- or allograft of bone marrow, peripheral blood and cord blood hematopoietic stem cells. Hematopoietic stem cells in the bone marrow, peripheral blood or cord blood cells are amplified *in vitro* with the polypeptide of the invention alone or in combination with hematopoietic growth factors such as G-CSF, GM-CSF, SCF, flk-2/flt3 ligand, IL-1, IL-3 and IL-6. Therefore, bone marrow cells need not be aspirated in an operating room, but a small amount of bone cells should be aspirated easily in a short time at an outpatient clinic which will be sufficient for transplantation. The physical burden of a cell donor, the labor of a medical staff, and the medical cost, associated with bone marrow aspiration, can be saved.

Among the polypeptides of the invention, the following 4 polypeptides described below are particularly preferred.

10 (i) The following polypeptide (a) or (b):

- (a) a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 1;
15 (b) a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 1 with deletion, substitution or addition of one or more amino acids and having BPA or GPA on human bone marrow cells.

15 (ii) The following polypeptide (a) or (b):

- (a) a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 4;
20 (b) a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 4 with deletion, substitution or addition of one or more amino acids and having BPA or GPA on human bone marrow cells.

25 (iii) The following polypeptide (a) or (b):

- (a) a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 8;
25 (b) a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 8 with deletion, substitution or addition of one or more amino acids and having BPA or GPA on mouse bone marrow cells.

30 (iv) The following polypeptide (a) or (b):

- (a) a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 12;
30 (b) a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 12 with deletion, substitution or addition of one or more amino acids and having BPA or GPA on rat bone marrow cells.

35 The "deletion, substitution or addition" mentioned herein can be generated by conventional techniques at the time of the filing of this application, e.g. site-specific mutagenesis (Zoller et al., Nucleic Acids Res. 10, 6487-6500, 1982).

KPB-M15 cell line capable of producing the polypeptide (i) above has been deposited with the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry (1-3, Higashi 1-chome, Tsukuba City, Ibaraki Pref., Japan) under Accession No. FERM BP-5850 (date of deposit: March 5, 1997).

(2) The Gene of the Invention (the 2nd Invention)

The gene of the invention is that of a mammalian origin encoding a polypeptide with BPA or GPA on the bone marrow cells.

45 BPA and GPA can be detected as described above.

The gene of the invention can be synthesized from mRNA by PCR on the cDNA from mammalian mRNA as a template, using a forward and a reverse primers synthesized based on the nucleotide sequence shown in SEQ ID NO: 1. Specific examples of the mammals to be used in the invention include, but are not limited to, human and mouse. Specific examples of the primers for PCR include, but are not limited to, the primer shown in SEQ ID NO: 6 and the primer shown in SEQ ID NO: 7. mRNA preparation, cDNA synthesis and PCR can be carried out by conventional methods.

50 The gene of the invention will be useful as a template essential for a large scale production of a recombinant mammalian SCGF using recombinant DNA technology. SCGF-producing cells can be identified by *in situ* or Northern hybridization with a part of the DNA sequence of the gene. The genomic DNA for SCGF can be similarly isolated and characterized. The present gene of the invention can contribute to the diagnosis of various hematopoietic diseases or elucidation of the pathogenesis by analysis for deletion, mutation, and suppressed or excessive expression of the gene. The present invention is accordingly applicable to gene therapy, e.g. introduction of a deleted gene, replacement of a mutated gene with a normal one, suppression of excessive gene expression with an antisense DNA (RNA), and so on.

EP 0 860 447 A1

It is possible to isolate and characterize other mammalian SCGF genes highly homologous with human and mouse ones, using a part of the gene of the invention as a probe. Knock-out and transgenic animals constitutively lacking and expressing SCGF gene respectively, are quite significant in analysis for pathogenesis disease model animals and SCGF-concerned hematopoietic mechanism *per se*.

5 Among the genes of the invention, the following 4 genes are particularly preferred.

(i) A gene encoding the following polypeptide (a) or (b):

- 10 (a) a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 1;
(b) a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 1 with deletion, substitution or addition of one or more amino acids and having BPA or GPA on human bone marrow cells.

(ii) A gene encoding the following polypeptide (a) or (b):

- 15 (a) a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 4;
(b) a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 4 with deletion, substitution or addition of one or more amino acids and having BPA or GPA on human bone marrow cells.

(iii) A gene encoding the following polypeptide (a) or (b):

- 20 (a) a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 8;
(b) a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 8 with deletion, substitution or addition of one or more amino acids and having BPA or GPA on mouse bone marrow cells.

25 (iv) A gene encoding the following polypeptide (a) or (b):

- (a) a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 12;
(b) a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 12 with deletion, substitution or addition of one or more amino acids and having BPA or GPA on rat bone marrow cells.

30 The "deletion, substitution or addition" can be generated by site-specific mutagenesis, as described above.

An *E. coli* carrying the gene described in (i) above (*Escherichia coli* SHDM11610C) has been deposited with the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry (1-3, Higashi 1-chome, Tsukuba City, Ibaraki Pref., Japan) under Accession No. FERM BP-5849 (date of deposit: March 4, 1997); an *E. coli* carrying the gene described in (ii) above (*Escherichia coli* HSCGF) has been deposited with the same institute under Accession No. FERM BP-5986 (date of deposit: June 19, 1997); an *E. coli* carrying the gene described in (iii) above (*Escherichia coli* MSCGF) has been deposited with the same institute under Accession No. FERM BP-5987 (date of deposit: June 19, 1997); and an *E. coli* carrying the gene described in (iv) above (*Escherichia coli* RSCGF) has been deposited with the same institute under Accession No. FERM BP-6063 (date of deposit: August 19, 1997).

(3) The Vector of the Invention (the 3rd Invention)

The vector of the invention carries the gene of the invention described above. The vector may have additional DNA region, e.g. a replication initiator and terminator, a selective marker gene(s), a promoter to enhance the expression of the gene of the invention, a poly(A) (polyadenylation) signal, and so forth.

The vector of the invention can be prepared by inserting the gene of the invention into the restriction site of a known vector, such as plasmid, cosmid, phage or virus, digested with an appropriate restriction enzyme. Specific examples of the known vectors to be used in the invention include, but are not limited to, pBR322, pACYC, pUC, pGEM, pBC, pGA, Bluescript, pK21, pRSV, pcD, pGEX, CDM8, SHDM, pBV, pSV, pMT2, pYAC, pWE15, pHEBo, EMBL, Charon, M13, λ zap, λ SHDM, λ gt10 and λ gt11 vectors.

(4) The Transformant of the Invention (the 4th Invention)

56 The transformant of the invention is transformed with the vector of the invention described above. The transformant of the invention can be from any organism species if transformed with the above vector.

The transformant of the invention can be prepared by transforming an appropriate host with the above vector. *E. coli*, yeast, insect and mammalian cells are candidates of the host to be used in the invention. More specifically, the

hosts include, but are not limited to, *E. coli* strains such as HB101, JM109, MC1061, BL21, XL1-Blue, SURE, DH1, DH5; yeast strains such as HIS/LI, HF7c; insect cells such as BmN, Sf cells; and mammalian cells such as CHO, COS, MOP, c127, Jurkat, WOP, HeLa, Namalwa cells. An appropriate method of transformation should be selected depending on the host; the calcium phosphate precipitation or electroporation for *E. coli*; the lithium acetate method, spheroplast fusion or electroporation for yeast; viral infection for insect cells; the calcium phosphate precipitation, protoplast fusion, lipofection, the erythrocyte ghost method, liposome fusion, the DEAE-dextran method, electroporation or viral infection for mammalian cells.

(5) The Antibody of the Invention (the 5th Invention)

The antibody of the invention reacts specifically with the polypeptide of the invention described above. The antibody of the invention can be either a monoclonal or a polyclonal antibody if specifically reactive with the above polypeptide. The antibody of the invention can be prepared by conventional methods. *In vivo* method and *in vitro* method are a single or multiple immunization, at several week interval, with antigen and immunocompetent cells plus adjuvant, respectively. Specific examples of the immunocompetent cells capable of producing the antibody of the invention include spleen, tonsil and lymph node cells. Whole molecule of the polypeptide of the invention need not be necessarily used as an antigen, but a part of the polypeptide may well be antigenic. A short polypeptide, particularly of about 20 amino acids, should be chemically linked to a highly antigenic carrier protein such as Keyhole Lympet hemocyanin or bovine serum albumin. Alternatively, the polypeptide is covalently bound to a branched skelton polypeptide such as lysine-core MAP (Posnett et al., J. Biol. Chem. 263, 1719-1725, 1988; Lu et al., Mol. Immunol. 28, 623-630, 1991; Briand et al., J. Immunol. Methods 156, 255-265, 1992). Complete or incomplete Freund's adjuvant and aluminium hydroxide gel can be used as the adjuvant. Animals to be immunized with the antigen include mouse, rat, rabbit, sheep, goat, chicken, cow, horse, guinea pig and so forth. Blood is obtained from animals immunized, and polyclonal antibody immunoglobulin is purified from serum by ammonium sulfate precipitation, anion exchange, protein A or G chromatography. An antibody can be purified from eggs in the case of immunized chicken. Immunocompetent cells (immunized *in vitro* or recovered from the immunized animals as described above) are fused with parental cells, giving rise to hybridoma cells. Monoclonal antibody is purified from culture supernatants of the hybridoma cells or ascites of animals transplanted with the hybridoma cells intraperitoneally. Specific examples of the parental cells include X63, NS-1, P3U1, X63.653, SP2/0, Y3, SK0-007, GM1500, UC729-6, HM2.0 and NP4-1 cells. Alternatively, immunocompetent cells (immunized *in vitro* or recovered from the immunized animals) are infected with appropriate virus such as EB virus, resulting in immortalized, antibody-producing cells, from which monoclonal antibody can be prepared. Genetic engineering can be applied to antibody production. For example, an antibody gene can be amplified by PCR from immunocompetent cells (immunized *in vitro* or recovered from the immunized animals), and transferred into *E. coli* to produce the antibody. Alternatively, the antibody can be expressed as a fusion protein on the surface of a phage. immunoassay for SCGF concentration in patients tissues or organs, using the antibody of the invention, elucidates relationship between SCGF and pathogenesis or clinical course of various diseases. The antibody of the invention is versatile for diagnosis, treatment of diseases and efficient affinity purification of SCGF.

(6) The Antibody-Producing Organism of the Invention (the 6th Invention)

The microorganisms, animal cells or animals of the invention produce the antibody of the invention described above. Specific examples of the microorganisms, animal cells or animals include, but are not limited to, *E. coli* transformed with the gene encoding the antibody of the invention; a phage expressing the gene for antibody of the invention as a fusion protein on the surface, and the hybridoma cells described above.

(7) Method for Producing the Polypeptide of the Invention (the 7th Invention)

The polypeptide of the invention can be produced by the culture of cells carrying the gene of the invention described above. There exist two types of cells that express the gene of the invention; human placenta and KPBM15 cells naturally express the gene, and COS and CHO cells should be transfected with the gene. The polypeptide of the invention can be purified from the culture supernatants of the above cells using purification method of the invention described below. Alternatively, the polypeptide can be extracted from cellular lysates. The cells are broken by physical shearing using a clounce homogenizer or ultrasonication, or lysed with surfactants such as Triton X-100, Nonidet P-40 and sodium lauryl sulfate (SDS).

(8) Method to Purify the Polypeptide of the Invention (the 8th Invention)

The polypeptide of the invention can be purified using one or more of an anion exchange, a hydrophobic, a gel filtration, a pigment and lectin affinity, and a metal-chelating chromatography.

5 Crude sample is applied to an anion exchange, for example, DEAE-Sephadex column, washed to let unabsorbed proteins flow-through, and eluted with a linear increasing NaCl gradients. Crude sample is applied to a hydrophobic, for example, Octyl-Sepharose column, and flow-through fractions are collected. Crude sample is fractionated through a gel filtration, for example, Sephacryl S-200 HR column. Crude sample is applied to a pigment affinity, for example, Red- or Blue-Sepharose column, and flow-through and early eluted fractions are collected. Crude sample is applied to a lectin affinity carrier, for example, wheat germ agglutinin (WGA)-agarose or Concanavalin A (ConA)-Sepharose column, and flow-through fractions are collected. Crude sample is applied to a metal-chelating, for example, Cu²⁺-chelating Sepharose column, washed to let unadsorbed molecules flow-through, and eluted with a linear increasing glycine gradients.

(9) The Pharmaceutical Composition of the Invention (the 9th Invention)

15 The pharmaceutical composition of the invention comprises the polypeptide of the invention as an active ingredient. The pharmaceutical composition of the invention is administered alone or in combination with other hematopoietic growth factor(s) systemically or locally, and orally or parenterally. The composition is administered at an effective dose to ameliorate hematopoietic insufficiency by the hematopoietic activity of SCGF. However, the dosage should be flexible and proper, since the administration dose varies depending on the age, body weight, conditions and reactivity of a patient, route of administration and so on.

20 For oral administration, the pharmaceutical composition of the invention can be as a solid composition such as tablets, soft and hard capsules, pills, powder and granules, or a liquid composition such as solution, syrup and suspension. For parenteral administration, the pharmaceutical composition of the invention can be an endermic formulation for external use such as solution, suspension, emulsion, ointment, cream, gel, rosol; a suppository; or an injectable formulation for intravenous, intramuscular or subcutaneous injection.

25 A pharmaceutically inactive carrier for the pharmaceutical composition can be a diluent such as purified water, lactose, glucose, starch, mannitol, hydroxypropylcellulose, polyvinylpyrrolidone, magnesium aluminate metasilicate, gum-arabic, talc, a vegetable oil or yellow petrolatum. Further, pharmaceutically active additives can be any of conventional, pharmaceutically acceptable materials such as lubricants (magnesium stearate, etc.), disintegrators (fibrin calcium glycolate, etc.), stabilizers (human serum albumin, etc.) and resolution adjuncts (arginine, aspartic acid, etc.).

30 The solid composition for oral administration can be tablets formulation coated with one or more layers of white sugar, gelatin, hydroxypropyl-cellulose and hydroxypropylmethylcellulose phthalate to be dissolved in the stomach or small intestine. The liquid composition for oral administration can contain purified water, ethanol, solutions, syrups, suspensions, emulsions, elixirs and so on. Further, the composition can contain flavoring agents, preservatives and the like in accordance with appropriate standards for pharmaceutical combination.

35 The injectable formulation for intravenous, intramuscular or subcutaneous injection can contain, as a pharmaceutically inactive carrier, a diluent such as distilled water for injection, physiological saline, propylene glycol, polyethylene glycol, a vegetable oil (e.g., olive oil) or an alcohol (e.g., ethanol). In addition, the formulation can contain, as pharmaceutically active additives, preservatives, stabilizers, emulsifiers, buffers, dispersants, resolution adjuncts and the like in accordance with appropriate standards for pharmaceutical combination. The injectable formulations are sterilized by filter-sterilization, addition of a bactericide, or irradiation. Alternatively, a solid composition (such as a lyophilized preparation) can be restored with an aseptic distilled water for injection or the like before administration.

40 The pharmaceutical composition of the invention is used alone or in combination with other hematopoietic growth factor(s) (such as Epo, G-CSF, GM-CSF and SC) to ameliorate such hematopoietic insufficiency that could not have been improved with known hematopoietic growth factors. Hematopoietic insufficiency to be treated with the pharmaceutical composition of the invention include hematopoietic diseases due to quantitative or qualitative abnormalities in hematopoietic stem cells; aplastic anemia, paroxysmal nocturnal hemoglobinuria, chronic myelocytic leukemia, polycythemia vera, essential thrombocythemia, myelofibrosis, myelodysplastic syndrome and acute leukemia; and hematological diseases such as megaloblastic anemia, AIDS, multiple myeloma, metastatic cancer of the bone marrow, and drug-induced myelosuppression. The pharmaceutical composition of the invention is effective to prevent and ameliorate hematopoietic insufficiency due to irradiation or chemotherapy of the patients with malignant lymphoma or other solid tumors.

45 The pharmaceutical composition of the invention is applicable to gene therapy; supplementation of a normal gene into enzyme deficiencies (e.g. adenosine deaminase deficiency); replacement of an abnormal gene with a normal gene in genetic mutations (e.g. hemoglobinopathy); and introduction of a gene encoding growth inhibitory factors against cancer cells. Since quiescent hematopoietic stem cells can enter the cell cycle with the composition of the invention alone or in combination with other hematopoietic growth factor(s) transfection efficiency of a retrovirus vector carrying

a normal gene or a gene of interest into those cells is remarkably improved. Once hematopoietic stem cells into which the gene has been introduced are transplanted, they continuously recruit mature blood cells carrying the gene to alleviate or cure the relevant genetic disorders.

5 (10) The λ Phage Vector of the Invention (the 10th Invention)

The λ phage vector of the invention has at least 2 functional DNA regions for replication in *E. coli* and for expression in mammalian cells with a flanking replication initiator and a terminator from a filamentous phage.

A filamentous phage is a bacteriophage with a single-stranded circular DNA, which specifically infects F factor-containing *E. coli*. Specific examples of the phage include M13, f1 and fd phages. "A replication initiator" is a nucleotide region which the filamentous phage recognizes to start DNA replication e.g. the nucleotide base sequence of the Nhel-DraIII region of M13 phage replication origin gene (ori). "A replication terminator" is a nucleotide region which the filamentous phage recognizes to stop DNA replication, e.g. the nucleotide sequence of the Aval-Rsal region of M13 phage ori gene. The λ phage vector of the invention should have at least 2 functional DNA regions for replication in *E. coli* and for expression in mammalian cells with a flanking replication initiator and a terminator of a filamentous phage. "A DNA region for replication in *E. coli*" is a replication initiation region (ori) of *E. coli*, e.g. the ColE1 ori. "A DNA region for expression in a mammalian cells" consists of at least a promoter and a poly(A) addition signal for efficient expression of a foreign gene based on DNA from a virus capable of infecting mammalian cells. A virus capable of infecting mammalian cells include SV40 virus, BK virus, papilloma virus, adenovirus, retrovirus, vaccinia virus, EB virus and so forth.

20 A λ phage vector is a vector from bacteriophage λ -derived DNA. Specific examples of λ phage vector include λ SHDM and λ CDM both described in Examples of the present invention, λ gt10, λ gt11, EMBL3, EMBL4 and Charon4A.

The vector of the invention and the method of the invention for isolating a gene described below are applicable to the search for other novel genes, and can contribute to the technical development in novel genes-related fields of genetic engineering and biotechnology.

25 (11) The Method of the Invention for Isolating a Gene (the 11th Invention)

The method of the invention for isolating a gene utilizes the λ phage vector of the invention described above. Specifically, a method consisting of the following 4 steps may be illustrated by example, but the method of the invention is not limited to this method.

A) First Step

mRNA is prepared from cells producing a protein of interest. cDNA is synthesized from the mRNA, and ligated into the cloning site between the replication initiator and terminator of the λ phage vector of the invention. A host cell is infected with the recombinant phage vector to provide a phage cDNA library. A protein of interest can be, but is not limited to, the polypeptide of the invention (SCGF). Any protein can be used if it has some activity or function assayable for screening. Cells producing a protein of interest can be, but are not limited to, KPB-M15 cells producing SCGF. Alternatively, a protein of interest can be detected with the specific antibody. mRNA can be prepared, and cDNA synthesized using conventional methods. Host cells to be infected can be conventional host cells such as *E. coli*.

B) Second Step

The specific differential phage cDNA library is made of clones that hybridize with a positive probe but not with a negative probe.

45 The positive probe is single-stranded cDNA (sscDNA) synthesized from the mRNA of the cells producing the protein of interest and subtracted with the mRNA of cells that closely resemble the above cells but do not produce the protein of interest. The negative probe is an sscDNA synthesized from the mRNA of the cells not producing the protein of interest. Differential cloning with the positive and the negative probes exclude the housekeeping cDNA clones irrelevant to the production of the protein of interest, leading to great reduction in the number of cDNA clones for screening. Methods other than differential cloning can be used for that purpose.

C) Third Step

55 Plasmids are prepared from the above-sorted cDNA clones the λ phage vector of the invention and transfected into a host cells capable of producing the protein of interest. The host cells producing the protein of interest are identified by screening assay for the activity or function or with a specific antibody.

Specific examples of the host cells capable of producing the protein of interest include, but are not limited to, COS-

1 cells.

D) Fourth Step

- 5 The plasmid is prepared from host cells such as *E. coli*, and then a gene of interest is isolated from the plasmid.

Examples

Hereinbelow, the present invention will be described in more detail with reference to the following Examples, which
10 should not be construed as limiting the scope of the invention.

Example 1: Preparation of mRNA from KPB-M15 Cells

Total RNA was prepared from KPB-M15 cells known to produce the polypeptide of the invention, according to the
15 method of Chomczynski and Sacchi (Anal. Biochem. 162, 156-159, 1987).

KPB-M15 cells were lysed in 25 mM sodium citrate buffer containing 4 M guanidine thiocyanate, 0.5% Sarkosyl and
0.1 M 2-mercaptoethanol (2-ME) (Solution D). The lysates were phenol/chloroform-extracted under acidic conditions
followed by precipitation of the mRNA in the aqueous phase with 2-propanol.

Oligotex dT30 beads (Takara, Ohtsu) were mixed with the total RNA solution at 37°C under NaCl of over 0.5 M.
20 After wash, mRNA bound to the beads was dissociated with 10 mM Tris-HCl buffer (pH 7.5) (TE) plus 1 mM EDTA.

Example 2: Synthesis of cDNA from KPB-M15 Cells (KPBM15 cDNA)

cDNA synthesis was carried out using ZAP-cDNA Synthesis Kit (Stratagene, CA, La Jolla).

Nucleic acid mixture containing Me-dCTP, a linker primer (Fig. 1) and a reverse transcriptase (RTase) was reacted
25 at 37°C with mRNA solution from KPB-M15 cells to synthesize the first strand DNA (1st Str). RNase H and DNA
polymerase I (DNAPolyI) were reacted at 16°C with the mixture to synthesize the second strand DNA (2nd Str). The
ends of the synthesized cDNA were made blunt with T4 DNA polymerase, ligated to EcoRI adaptor (Fig. 1) at 8°C with
30 T4 DNA ligase, and phosphorylated with T4 polynucleotide kinase (PNKinase). The cDNA was digested at 37°C with
Xhol, and size-fractionated by BioGel A50m column (BioRad, CA, Hercules) equilibrated with TE plus 0.1 M NaCl (STE)
to collect cDNA of over 500 base pairs (bp).

Example 3: Construction of λ CDM and λ SHDM Vectors

35 λ CDM and λ SHDM vectors were constructed by insertion of linearized CDMflit and SHDM plasmids, the former
of which was produced from CDM8 (Seed, Nature 329, 840-842, 1987), into λ phage vectors, respectively.

λ CDM was constructed as follows; the stuffer XbaI-HindIII region of CDM8 was replaced with a PRC/CMV
polylinker (Invitrogen, CA, San Diego) to develop construct CDMmcs. The EcoRV-EcoRI region in the polylinker was
40 replaced with a PBS (Stratagene) polylinker SmaI-EcoRI fragment, leading to the EcoRV site-eliminated CDMmcs(-v).
(SEQ ID NO: 3). The synthetic DNA (SEQ ID NO: 3), which has a part of the overlapping region between the M13 initiator
and terminator (Fig. 2) and an EcoRV site at its 5' end, was ligated with the HinfI-Rsal fragment to the DralII-SacII
45 region of CDMmcs(-v) to develop CDMflit; the EcoRV site was located between M13 initiator and terminator. On the
other hand, the λ phage vector of the invention was modified from λ Bluemid (Clontech, CA, Palo Alto); λ Bluemid was
digested with NotI to remove the NotI-NotI fragment, and the left and right arms were ligated. To eliminate, the Xhol site,
50 the NotI-NotI region-deleted fragment was digested with Xhol, blunt-ended with T4 DNA polymerase, and ligated with
T4 DNA ligase. The resultant vector was designated λ b-x. The CDMflit was linearized with EcoRV, and ligated to the
NotI site of λ b-x to develop λ CDM (Fig. 4).

SHDM was constructed as follows; CDMflit was digested with AatI, where a BamHI linker (CGGATCCG) was
55 ligated to introduce a BamHI site. The plasmid was digested with BamHI to provide 3 DNA fragments, of which the frag-
ment containing SV40 ori and Py ori was discarded. The remaining 2 fragments were ligated to develop CDMflit(-sv,
py). The Py ori cut out from CDMflit with NcoI was blunt-ended with T4 DNA polymerase and then introduced into the
NheI site of CDMflit(-sv, py) to develop CDMflit(-sv). CMV promoter was removed from CDMflit(-sv) with NruI and Hin-
dIII, and replaced with Hind III - Pvu II SV40 early promoter fragment from pSV2neo (Southern and Berg, J. Mol. Appl.
Genet. 1, 327-341, 1982) to develop SDMflit. A synthetic DNA of about 300 bp corresponding to the R region and a part
60 of the U5 region of HTLV-1 LTR was introduced into the HindIII site of SDMflit to develop SHDMflit. A fragment of SV40
16S splicing sequence was prepared from pL2 with Xhol-BanIII, and introduced into the SpeI site of SHDMflit to develop
SHDM (Fig. 3). SHDM was linearized with EcoRV and ligated to the NotI site of λ b-x to develop λ SHDM (Fig. 4).

Epo cDNA was inserted into λ SHDM and λ CDM vectors by the methods described in Examples 4 to 7 and

EP 0 860 447 A1

expressed in COS-1 cells. λ SHDM-bearing cells yielded in higher Epo production by 25% than other vector-bearing cells. Consequently, the inventors decided to use λ SHDM in the following Examples.

Example 4: Insertion of KPB-M15 Cell-Derived cDNA into λ SHDM Vector

5 λ SHDM vector was digested with Xhol and EcoRI to form a cDNA insertion site. The vector arms were fractionated from the Xhol-EcoRI fragment through a BioGel A50m column equilibrated with STE. The vector arms were dephosphorylated with calf intestine alkaline phosphatase (CIAP). The KPB-M15 cDNA from Example 2 above was ligated with T4 DNA ligase to the Xhol-EcoRI-digested, dephosphorylated λ SHDM vector.

10 Example 5: Phage Packaging of the KPB-M15 cDNA-bearing λ SHDM Vector

15 The cDNA-bearing vector in Example 4 was phage-packaged, using the freeze-thawed extract and the sonicated extract of Gigapack-Gold Packaging Extract Kit (Stratagene), and modulated with 50 mM Tris-HCl storage solution (SM) containing 0.1 M NaCl, 8 mM magnesium chloride ($MgCl_2$) and 0.01% gelatin, and a small amount of chloroform to provide a phage cDNA library (hereinafter referred to as " λ SHDM (KPB) phage"). SURE *E. coli* in 10 mM magnesium sulfate ($MgSO_4$) was infected with λ SHDM (KPB) phage, temperature melting agarose in mixed with NZYM (0.5% NaCl, 0.5% yeast extract, 0.2% $MgSO_4$ and 1% NZ amine), and seeded onto Luria-Bertani (LB medium; 0.5% NaCl, 1% bactotryptone and 0.5% yeast extract) agar plates. Plaques were counted after overnight culture; 1.67×10^6 pfu for the total λ SHDM (KPB) phage.

20 The phage clones randomly selected from each plaque were coinjected with a quite small amount of helper phage R408 into XL1-Blue *E. coli* in 10 mM $MgSO_4$ to develop a phagemid. The phagemid was infected into MC1061/P3/PCJ *E. coli* in NZYM, and cultured overnight on ampicillin (Amp) and tetracycline (TC) selective LB agar plates to form pSHDM (KPB) plasmid-carrying *E. coli* colonies. Plasmid DNA was prepared from Amp/TC-resistant colonies by alkaline lysis procedure (Birnboim and Doly, Nucleic Acids Res. 7, 1513-1523, 1979; Ish-Horowicz and Burke, Nucleic Acids Res. 9, 2989-2998, 1981), and digested with Xhol and EcoRI. A 500 bp-3 kb KPB-M15 cDNA was inserted in about 70% of the clones, as detected by agarose gel electrophoresis.

Example 6: Construction of a Differential cDNA Library

30 λ SHDM (KPB) phage in Example 5 was transferred onto duplicate nitrocellulose filters, lysed with alkali, neutralized and heated at 80°C for about 2 hours. The phage DNA fixed on each filter was hybridized with 32 P-labelled positive and negative probes, washed to remove unbound probes, and subjected to autoradiography. The clones both positive for the positive probe and negative for the negative probe were selected as the KPB-M15-specific differential phage library.

35 The KPB-M15-specific positive probe was prepared from KPB-M15 cDNA by subtraction; the KPB-M15 cDNA which hybridize with mRNA from SCGF-infertile MOLT-4 cells was excluded as genes common in both cells, and the remaining cDNA was the positive probe.

40 More specifically, 1st Str cDNA was synthesized from KPB-M15 mRNA (as described in Example 1) using an oligo(dT) primer and SuperScript™ R Tase (GIBCO-BRL, NY, Grand Island). KPB-M15 sscDNA was fractionated from the template mRNA hydrolyzed with alkali through a Sephadex G-50 (Pharmacia, Sweden, Uppsala) column equilibrated with STE, and annealed with an excess of MOLT-4 mRNA at 65°C for over 40 hours. The reaction mixture was applied to a hydroxyapatite (BioRad) column equilibrated with 0.12 M sodium phosphate buffer (pH 6.5); flow-through fractions were collected, and after alkali treatment, fractionated through Sephadex G-50 gel filtration. Fractions around the void volume were collected as the positive probe. MOLT-4 mRNA was prepared from total RNA as described in Example 1; MOLT-4 total RNA was applied to an oligo(dT) cellulose column equilibrated with 10 mM Tris-HCl buffer (pH 7.5) containing 0.5 M potassium chloride (KCl), and bound mRNA was eluted with 10 mM Tris-HCl buffer (pH 7.5).

45 sscDNA was synthesized, as described above, from MOLT-4 mRNA as described in Example 1, and used as the negative probe.

50 The probes were labelled using Multilabelling Kit (Amersham, England, Buckinghamshire, Amersham); the KPB-M15 specific sscDNA or the MOLT-4 sscDNA was heated at 95°C, cooled rapidly on ice, and mixed with random primers, 32 P-labelled dCTP and Klenow enzyme to synthesize 32 P-labelled probes. Unreacted 32 P-labelled dCTP was removed using a Sephadex G-50 column equilibrated with STE.

55 Example 7: Expression Cloning of SCGF cDNA

Copies of pSHDM(KPB)-carrying *E. coli* prepared in Example 6 were individually cultured for each 48 clones to make up into a pool. Crude plasmid DNA was prepared from each pool by alkaline lysis procedure. Purified mix plasmid

cDNA was purified by quillibrium centrifugation in cesium chloride-ethidium bromide gradients.

COS-1 cells (Accession No. ATCC CRL-1650; SV40-transformed fibroblastoid cell line from a simian kidney, were transfected at 37°C under 5% CO₂ in air with 3.3 µg/ml plasmid cDNA in Dulbecco's modified Eagle medium (DMEM, Nissui, Tokyo) containing 100 µg/ml DEAE-dextran and 100 µM chloroquine (a transfection medium). The cells were incubated in DMEM-10% FCS containing 10% dimethylsulfoxide (DMSO), and then cultured overnight in DMEM-10% FCS. Another cycle of transfection, i.e. double transfection was followed by 3- to 5- day cultures in serum-free DMEM. The COS-1 culture supernatants were concentrated as follows; they were diluted with over 7 volumes of 20 mM HEPES buffer (pH 6.0) containing 0.01% Tween 80, applied to a DEAE-Sephadel (Pharmacia) column equilibrated with 20 mM HEPES buffer (pH 6.0) containing 20 mM NaCl and 0.01% Tween 80, washed thoroughly with the same buffer, and eluted with 20 mM HEPES buffer (pH 6.0) containing 0.25 M NaCl and 0.01% Tween 80.

The concentrated COS-1 culture supernatants were screened for BPA. BPA on human bone marrow cells was assayed as follows; human bone marrow cells (2.5 mp) were aspirated from the sternum of healthy adult volunteer after obtaining informed consent. Low density mononuclear cells were separated with Ficoll Pack (Pharmacia), washed with IMDM (GIBCO) 3 times, suspended in IMDM-10% FCS (CSL, Australia, Melbourne) 10 ml and incubated at 37°C for 15 75 minutes. Non-adherent cells (5×10^4 /ml) were cultured in IMDM containing the COS-1 culture supernatants, 1 unit/ml recombinant human Epo (Espo; Kirin-Sankyo, Tokyo), 20% FCS, 5×10^{-5} M 2-ME and 0.3% Bacto-agar. After 14-day culture, erythroid bursts were enumerated under an inverted microscope.

Pool Nos. 71, 86, 116 and 130 showed relatively high BPA at the initial screening for 137 pools. A single plasmid cDNA was prepared from the clones in each selected pool, and transfected into COS-1 cells again. The clone No. 116-10C was highly positive for BPA at the secondary screening. Sequencing on 373ADA autosequencer (Perkin-Elmer Applied Biosystems, CT, Norfolk), indicated that the clone No. 116-10C had cDNA with the nucleotide sequence shown in SEQ ID NO: 2. No homology with the databases in the EMBL and GenBank (Lipman and Pearson, Science 227, 1435-1441, 1985) was found for the cDNA sequence in the total or most of the coding region, though only one short DNA fragment showed partially high homology with the 3' untranslated region of the cDNA clone No. 116-10c. A long open reading frame encoded a 245-amino acid polypeptide with about 20 hydrophobic amino acids at an N-terminal region (Hopp and Wood, Proc. Natl. Acad. Sci. USA 78, 3824-3828, 1981) as shown in SEQ ID NO: 1. No homology with the database in the Swiss-Prot was found for the amino acid sequence.

Example 8: Assay for the Hematopoietic Activity in the Culture Supernatant of SCGF cDNA Clone No. 116-10C-Expressing COS-1 Cells

COS-1 cells were transfected with 1.3 µg/ml clone No. 116-10c plasmid cDNA as described in Example 7. BPA of the culture supernatant was assayed as described in Example 7. GPA was assayed as follows; human bone marrow cells (5×10^4 /ml) prepared in Example 7 were cultured in IMDM containing the COS-1 culture supernatants, 5 ng/ml recombinant human GM-CSF (Genzyme, MA, Cambridge), 20% FCS, 5×10^{-5} 2-ME and 0.3% Bacto-agar. After 10-day culture, GM colonies consisting of granulocytes and macrophages were enumerated under an inverted microscope. Dose-dependent BPA and GPA were observed (Fig. 5).

Example 9: Assay for of the Hematopoietic Activity in the Serum-Free Culture Supernatant of KPB-M15 Cells

KPB-M15 cells ($1-2 \times 10^6$ /ml) grown in RPMI-1640 (GIBCO)-10% FCS were transferred to the serum-free culture for 3-4 days. BPA and GPA of the culture supernatants were assayed as described in Examples 7 and 8, respectively. Dose-dependent BPA and GPA were observed (Fig. 6). On the other hand, little activity was seen in the culture supernatants of K562 and MOLT-4 cells prepared under the same conditions.

Example 10: Preparation of an Anti-SCGF Polyclonal Antibody

The pGEX-2T vector (Pharmacia; Fig. 7) was digested with NotI, blunt-ended with T4 DNA polymerase, and by digested with BamHI to form an insertion site. NcoI-BamHI linker (Fig. 7) and 116-10C NcoI-XbaI DNA fragment were ligated to the vector with T4 DNA ligase to develop circular pGEX-2T(116-10C). The pSHDM(116-10C) plasmid cDNA was digested with XbaI, blunt-ended with T4 DNA polymerase, and digested with NcoI to develop 116-10c NcoI-XbaI DNA fragment. JM109 *E. coli* was transformed with PGEX-2T(116-10C), and induced with isopropyl β-D-thiogalactoside (IPTG) to produce glutathione S-transferase/116-10C fusion protein (GST/116-10C). The inclusion body was lysed with urea, and the GST/116-10C fusion protein was affinity purified through a glutathione-Sepharose (Pharmacia) column. The fusion protein was digested with thrombin, and 116-10C protein was purified through a MonoQ (Pharmacia) column. Rabbits were immunized with the 116-10C SCGF protein and Freund's complete adjuvant (DIFCO, MI, Detroit) 3 times at 2-week intervals. Anti-serum was harvested 2 weeks after the final boost and the antibody was purified through a protein A-Sepharose (Pharmacia) column. The polyclonal antibody was confirmed to react with 116-10C

protein by enzyme-linked immunosorbent assay (ELISA).

Example 11: Preparation of an Anti-SCGF Monoclonal Antibody

- 5 A monoclonal antibody was prepared according to the method of Oi and Herzenberg (Selected Methods in Cellular Immunology, Mishell and Shiigi (eds.), San Francisco, WH Freeman Publishing, pp. 351-372, 1981). Briefly, BALB/C mice were immunized twice at 3-week interval with any of 116-10C protein as described in Example 10, a partially purified SCGF from culture supernatants of mitogen-stimulated human peripheral blood mononuclear cell, or a partially purified SCGF as described in Example 20 and Freund's complete adjuvant. Spleen cells were harvested 3 days after
10 the final boost, and mixed at the same ratio with a mouse myeloma cell line P3x63-Ag8.653 (1.5×10^8) (Koehler and Milstein, *Nature* 256, 495-497, 1975). They were fused with 50% polyethylene glycol 4,000. Hybridoma cells were selected in HAT medium (hypoxanthine, aminopterin and thymidine) up to day 11, fed with thymocytes on day 23, and then transferred to HT medium (hypoxanthine and thymidine). Two weeks thereafter, the hybridoma cells were cloned on the thymocyte feeder by limiting dilution. The cloned anti-SCGF antibody-producing hybridoma cells were administered intraperitoneally to BALB/c mice pretreated with pristane (0.5 ml/mouse), and ascites were harvested about 2 weeks afterwards. The antibody was purified from culture supernatants of the hybridoma cells or ascites through a protein G-Sepharose column. The antibody was confirmed to react with SCGF by ELISA. The effect of this purified anti-SCGF monoclonal antibody on SCGF activity was tested; serially diluted antibodies were added to partially purified SCGF, and incubated at 37°C for 2 hours and then at 4°C overnight. The monoclonal antibody specifically neutralized
15 BPA and GPA of SCGF (Fig. 8).
- 20 BPA and GPA of SCGF (Fig. 8).

Example 12: Purification of SCGF through DEAE-Sephacel

- 25 The culture supernatants of KPB-M15 cells as described in Example 9 was mixed with 6.5 volumes of 20 mM phosphate buffer (pH 6.0) and 1/100 volume of 1% Tween 80 to adjust salt concentration and pH. It was applied to a DEAE-Sephacel column equilibrated with 20 mM phosphate buffer (pH 6.0) containing 20 mM NaCl and 0.01% Tween 80 (all the buffers used in the following purification of SCGF contained 0.01% Tween 80), washed thoroughly with the same buffer, and eluted with a linear NaCl gradient (0.02-0.5 M). Salt concentration was adapted to be physiological through a PD-10 column equilibrated with 20 mM phosphate buffer (pH 7.4) containing 0.15 M NaCl. BPA in each fraction was assayed as described in Example 7. BPA was found in fractions eluted at about 0.1 M NaCl (Fig. 9).

Example 13: Purification of SCGF through Octyl-Sepharose

- 35 The culture supernatants of KPB-M15 cells as described in Example 9 was mixed with 2.56 g of NaCl and 1% Tween 80 to adjust the concentrations to 4M and 0.01%, respectively. It was applied to an octyl-Sepharose CL-4B (Pharmacia) column equilibrated with 20 mM phosphate buffer (pH 7.4) containing 4M NaCl, washed thoroughly with the same buffer, and eluted with a linear NaCl gradient (4-0.02 M). BPA in each fraction was assayed as described in Example 12. BPA was found in passing through fractions (Fig. 10).

40 Example 14: Purification of SCGF through Cu²⁺ chelating-Sepharose

- The culture supernatants of KPB-M15 cells as described in Example 9 was dialyzed against 10 mM phosphate buffer (pH 7.4) containing 0.5 M NaCl. It was applied to a Cu²⁺ chelating-Sepharose CL-4B (Pharmacia) column equilibrated with the same buffer, washed thoroughly with the same buffer, and eluted with a linear glycine gradient (0-0.1 M). BPA in each fraction was assayed as described in Example 12. BPA was found in fractions eluted at about 35 mM glycine (Fig. 11).

Example 15: Purification of SCGF through ConA-Sepharose

- 50 The culture supernatant of KPB-M15 cells as described in Example 9 was dialyzed against 20 mM Tris-HCl buffer (pH 7.4) containing 0.15 M NaCl. It was applied to a ConA-Sepharose CL-4B (Pharmacia) column equilibrated with the same buffer, washed thoroughly with the same buffer, and eluted with a linear α-methylmannose gradient (0-0.5 M). BPA in each fraction was assayed as described in Example 12. BPA was found in flow-through fractions (Fig. 12).

55 Example 16: Purification of SCGF through WGA Agarose

- The culture supernatants of KPB-M15 cells as described in Example 9 was dialyzed against 10 mM phosphate buffer (pH 7.4) containing 0.15 M NaCl. It was applied to a WGA-agarose (Seikagaku Corp., Tokyo) column equilibrated

EP 0 860 447 A1

with the same buffer, washed thoroughly with the same buffer, and eluted with a linear N-acetylglucosamine gradient (0-0.2 M). The fractions were dialyzed against IMDM containing 0.01% Tween, and BPA in each fraction was assayed as described in Example 7. BPA was found in flow-through fractions (Fig. 13).

5 Example 17: Purification of SCGF through Blue-Sepharose

The culture supernatant of KPB-M15 cells as described in Example 9 was dialyzed against 50 mM Tris-HCl buffer (pH 7.0) containing 50 mM NaCl. It was applied to a Blue-Sepharose CL-6B (Pharmacia) column equilibrated with the same buffer, washed thoroughly with the same buffer, and eluted with a linear NaCl gradient (0.05-1.5 M). BPA in each fraction was assayed as described in Example 12. BPA was found in flow-through fractions (Fig. 14).

Example 18: Purification of SCGF through Red-Sepharose

The culture supernatants of KPB-M15 cells as described in Example 9 was dialyzed against 50 mM Tris-HCl buffer (pH 7.0) containing 50 mM NaCl. It was applied to a Red-Sepharose CL-6B (Pharmacia) column equilibrated with the same buffer, washed thoroughly with the same buffer, and eluted with a linear NaCl gradient (0-1.5 M). BPA in each fraction was assayed as described in Example 12. BPA was found in the later half of flow-through fractions (Fig. 15).

Example 19: Fractionation of SCGF through Sephadryl S-200HR

20 The active fractions eluted through the Cu²⁺ chelating-Sepharose column shown in Example 14 were applied to a Sephadryl S-200HR (Pharmacia) column equilibrated with 20 mM phosphate buffer (pH 7.4) containing 0.15 M NaCl. BPA in each fraction was assayed as described in Example 7. BPA was found bimodally at broad range from 20 kD to 80 kD in molecular mass (Fig. 16).

25 Example 20: Sequential Purification of SCGF

The culture supernatants of KPB-M15 cells as described in Example 9 was diluted with 6.5 volumes of distilled water to adjust the ionic strength. It was applied to a DEAE-Sephacel column equilibrated with 20 mM HEPES-NaOH buffer (pH 6.0) containing 20 mM NaCl, washed thoroughly with the same buffer, and eluted with a linear NaCl gradient (0.02-0.5 M). Fractions eluted at 0.1-0.25 M NaCl were collected.

The DEAE-Sephacel fractions were applied to a Cu²⁺ chelating Sepharose column equilibrated with 20 mM HEPES-NaOH buffer (pH 7.4) containing 0.5 M NaCl, washed thoroughly with the same buffer, and eluted with a linear glycine gradient (0-0.2 M). Fractions eluted at about 35 mM glycine were collected. The fractions were dialyzed against 20 mM HEPES-NaOH buffer (pH 6.0) containing 20 mM NaCl, applied to a DEAE-Sephacel mini-column equilibrated with the same buffer, washed thoroughly with the same buffer, and eluted with the same buffer containing 0.5 M NaCl.

The condensed fractions were applied to a Sephadryl S-200HR column for gel filtration. BPA in each fraction was bimodal as in Example 19.

40 The purified fractions through the gel filtration were applied to tandemly united columns of Blue-Sepharose CL-6B (upstream) and DEAE-Sephacel (downstream) both equilibrated with 20 mM HEPES-NaOH buffer (pH 7.0) containing 50 mM NaCl, washed thoroughly with the same buffer, then the upper column was detached, and eluted through the DEAE-Sephacel column with the same buffer containing 0.5 M NaCl. Table 1 shows BPA and protein recovery in the sequential purification.

45

Table 1

Summary of SCGF Purification				
	Volume (ml)	Absorbance at 280 nm	Total Absorbance at 280 nm	BPA (No. of Erythroid Bursts)
KPB-M15 Culture Supernatants	1500	-	-	17
Elution Fraction 1 through DEAE-Sephacel	375	0.168	63	-

Table 1 (continued)

Summary of SCGF Purification				
	Volume (ml)	Absorbance at 280 nm	Total Absorbance at 280 nm	BPA (No. of Erythroid Bursts)
5	Elution Fraction through Cu ²⁺ chelating Sepharose	29	0.221	6.4
10	Elution Fraction 2 through DEAE-Sepha-cell	1.84	1.9	35
15	Elution Fraction through SephadrylS-200HR	12.9	0.088	25
20	Elution Fraction through Blue-DEAE	3.9	0.075	21
25			1.13	30

20 Example 21: Amplification and Identification of a Human SCGF Variant by Reverse Transcriptase-Polymerase Chain Reaction

DNA fragments were synthesized as primers according to the nucleotide sequences within the SCGF gene (SEQ ID NO: 2), are predicted to encode the N- and C-terminal portion of the mature protein. A reverse transcriptase-polymerase chain reaction (RT-PCR) was performed on mRNA from human bone marrow as a template using the primers. The oligonucleotides shown in SEQ ID NOS: 6 and 7 were used as the forward and reverse primer, respectively. The oligonucleotides were synthesized based on the solid phase synthesis using a fully automated DNA synthesizer. Each oligonucleotide was purified through an OPC cartridge. An ssDNA was synthesized with an oligo(dT) primer from poly A⁺ RNA 1 µg from human bone marrow (Clontech) in reaction solution 20 µl according to the protocol of SuperScript™ Preamplification System Kit (GIBCO/BRL). PCR was performed with Taq DNA polymerase (2.5 units; Takara) in reaction solution 100 µl using a part of the ssDNA as a template. PCR was carried out in the presence of 10% DMSO using 50 µM forward and reverse primers. One PCR cycle consisted of denaturation at 94 °C for 1 minute, annealing at 55°C for 2 minutes and extension at 72°C for 2 minutes in that order; total 30 cycles in the present invention. The 30th extension was at 72°C for 5 minutes. The RT-PCR products were fractionated by agarose gel electrophoresis. A DNA fragment around 960 bp was cut out from the gel, purified according to the protocol of QIA Quick Gel Extraction Kit (Qiagen), and eluted with TE buffer [10 mM Tris buffer (pH 8), 1 mM ethylenediamine tetraacetic acid disodium (EDTA) (pH 8)] 30 µl. The purified DNA fragment (9 µl) was inserted into pT7Blue(R) vector 1 µl according to the protocol of T-Vector Kit (Novagen). XL-1 Blue *E. coli* was transformed with the vector, and ampicillin-resistant cDNA-carrying *E. coli* was cloned. The RT-PCR product inserted in pT7Blue(R) vector was sequenced using DNA Sequencer Model 4000 (LI-COR). SequiTherm EXCEL™ Long-Read DNA Sequence Kit-LC (Epicentre Technologies) was used as specific reagents for sequencing according to the manufacturer's instructions. Five clones had identical nucleotide sequences. The nucleotide sequence predicted to encode the mature protein is shown in SEQ ID NO: 5 and its deduced amino acid sequence is shown in SEQ ID NO: 4. The cDNA was of an SCGF variant; 78 amino acids from position 196 to 273 in SEQ ID NO: 4 are added to position between 195 and 196 of SCGF (SEQ ID NO: 1).

45 Example 22: Cloning of Mouse SCGF cDNA

(1) Preparation of a cDNA Library from Mouse Stromal Cell Line MC3T3-G2/PA6

50 mRNA (about 30 µg) was prepared from mouse calvaria-derived stromal cell line MC3T3-G2/PA6 (1×10^8) (RIKEN Cell Bank: Accession No. RCB 1127) using Fast Track mRNA Extraction Kit (Invitrogen). The reagents were used according to the manufacturer's instructions. A double-stranded (ds) cDNA was synthesized with oligo(dT) primers from the mRNA (5 µg) using cDNA Synthesis System (GIBCO/BRL). cDNA fragments of about 1.5 kb - 2.2 kb were recovered by agarose gel electrophoresis. SuperScript™ RNase H - RTase (Invitrogen) was used instead of Moloney Murine Leukemia Virus (M-MLV) RTase in the Extraction Kit. The ssDNAs for the SII linker 11 mer (SEQ ID NO: 10) and 8 mer (SEQ ID NO: 11) were synthesized using 380A/DNA synthesizer (Applied Biosystems), and 50 µg each was phosphorylated with T4 polynucleotide kinase (Takara). The phosphorylated linkers (11 mer: 4 µg and 8 mer: 2.9 µg) were ligated to the dsDNA synthesized above, and subjected to agarose gel electrophoresis to recover dsDNA fragments

of about 1.5 kb - 2.2 kb. A cloning vector, pAMoPRC3Sc (Japanese Unexamined Patent Publication No. 06-823021; Sasaki et al., J. Biol. Chem. 268, 22782-22787, 1993) 24 µg was digested with SfiI and subjected to agarose gel electrophoresis to recover DNA fragments of about 8.8 kb. The pAMoPRC3Sc-derived SfiI fragment (8.8 kb) 2 µg was ligated to the dsDNA purified above, mixed with transfer RNA (tRNA) 5 µg, and ethanol-precipitates were dissolved in TE buffer 20 µl. LE392 *E. coli* (Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Springs Harbor Press, Plain View, N.Y., 2nd Ed., 1989) was transformed with the above DNA solution by electroporation (William et al., Nucleic Acids Res., 16, 6127-6145, 1988) to obtain about 250,000 clones of an ampicillin-resistant AMo(PA6) cDNA library.

(2) Cloning of Mouse SCGF cDNA

The ampicillin-resistant AMo(PA6) cDNA library clones were individually distributed, 20,000 to a pool, to make up a total of 50 pools. Plasmid was prepared from each pool by alkaline lysis procedure. PCR was carried out with the plasmid DNA as a template and Taq polymerase (Takara), using a forward primer (SEQ ID NO: 6) and a reverse primer (SEQ ID NO: 7). One PCR cycle consisted of denaturation at 94°C for 1 minute, annealing at 55°C for 2 minutes and extension at 72°C for 2 minutes in that order; total 30 cycles in the present invention. The 30th extension was at 72°C for 5 minutes. The RT-PCR products were fractionated by agarose gel electrophoresis. Ampicillin-resistant clones in pool No. 21 exhibited DNA amplification at about 960 bp, and re-seeded onto 96-well plates at a density of about 300 clones/well. PCR was performed with the *E. coli* DNA in each sub-pool as a template. Pool No. 1C4 exhibited DNA amplification at about 960 bp, then the ampicillin-resistant clones in the pool were re-seeded so as to contain 1 clone/well. Clone No. 21-1C4-5H6 exhibited DNA amplification. The nucleotide sequence of the clone was determined using DNA Sequencer Model 4000 (LI-COR) as in Example 21. The nucleotide sequence predicted to encode the mature protein in SEQ ID NO: 9 and its deduced amino acid sequence in SEQ ID NO: 8. The cDNA was of a mouse SCGF which is highly homologous with the human SCGF variant cDNA.

Example 23: Cloning of Rat SCGF

DNA fragments predicted to encode untranslated regions within the mouse SCGF gene (SEQ ID NO: 9) were synthesized as primers. RT-PCR was performed on a sscDNA prepared from the RNA of rat osteosarcoma cell line ROS-17/2.8-5 (RIKEN Cell Bank: Accession No. RCB0462) as a template using the above primers. ROS-17/2.8-5 cells were cultured in 60 mm plates until confluent. Total RNA was prepared from the cells using ISOGEN solution (Nippon Gene, Toyama Pref.) 1 ml. An sscDNA was synthesized with an oligo(dT) primer from the total RNA 5 µg in reaction solution 20 µl according to the protocol of SuperScript™ Preamplification System Kit (GIBCO/BRL). PCR was performed with EX Taq DNA polymerase (2.5 units; Takara) in reaction solution 100 µl using a part of the sscDNA as a template and 50 µM forward and reverse primers. The oligonucleotides shown in SEQ ID NOs: 14 and 15 were used as a forward and reverse primer, respectively, which were prepared using a fully automated DNA synthesizer, and purified through an OPC cartridge. One PCR cycle consisted of denaturation at 94°C for 1 minute, annealing at 55°C for 2 minutes and extension at 72°C for 2 minutes in that order; total 30 cycles in the present invention. The 30th extension was at 72°C for 5 minutes. The RT-PCR products were fractionated by agarose gel electrophoresis. A DNA fragment around 960 bp was cut out from the gel, purified according to the protocol of QIA Quick Gel Extraction Kit (Qiagen), and eluted with TE buffer 30 µl. The purified DNA fragment (9 µl) was inserted into pT7Blue(R) vector 1 µl according to the protocol of T-Vector Kit (Novagen). XL-1 Blue *E. coli* was transformed with the vector, and ampicillin-resistant cDNA-carrying *E. coli* was cloned. The RT-PCR product inserted in pT7Blue(R) vector was sequenced using DNA Sequencer Model 4000 (LI-COR). SequiTherm EXCEL™ Long-Read DNA Sequence Kit-LC (Epicentre Technologies) was used as specific reagents for sequencing according to the manufacturer's instructions. Five clones had identical nucleotide sequences. The nucleotide sequence predicted to encode the mature protein is shown in SEQ ID NO: 13 and its deduced amino acid sequence in SEQ ID NO: 12. The cDNA was of a rat SCGF highly homologous with the human SCGF variant cDNA.

Example 24: Structural Analysis of Human SCGF Polypeptide Produced in Animal Cells

(1) Construction of Plasmid pAGE-SCGF β for the Expression of Human SCGF in an Animal Cell

Human expression vector pAGE-SCGF β was constructed by ligation of a HindIII-KpnI fragment from the known mammalian expression vector pAGE210 (WO96-34016) to the DNA SEQ ID NO: 1 encoding the SCGF polypeptide (Fig. 17).

Briefly, pAGE210 3 µg was digested with HindIII and KpnI, and fractionated by agarose gel electrophoresis. A DNA fragment around 9 kb was cut out from the gel, purified according to the protocol of QIA Quick Gel Extraction Kit (Qiagen), and eluted with TE buffer 30 µl.

A cDNA encoding the mature protein (SEQ ID NO: 1) was prepared by PCR from the human SCGF cDNA (clone

No. 116-10C) described in Example 7. PCR was carried out on human SCGF cDNA clone No. 116-10C (about 100 ng) as a template in reaction solution 50 µl with Native Pfu polymerase (1.25 units; Stratagene) and 10% DMSO, using 50 µM forward and reverse primers. The oligonucleotides shown in SEQ ID NOs: 14 and 15 were used as a forward and reverse primer, respectively, which were synthesized using a fully automated DNA synthesizer, and purified through an OPC cartridge. One PCR cycle consisted of denaturation at 94°C for 1 minute, annealing at 50°C for 1 minutes and extension at 72°C for 2 minutes; total 30 cycles in the present invention. The 30th extension was at 72 °C for 5 minutes. The RT-PCR products were phenol chloroform-extracted, ethanol-precipitated, digested with HindIII and KpnI, and fractionated by agarose gel electrophoresis. A DNA fragment around 770 bp was cut out from the gel, purified and eluted with TE buffer. The HindIII-KpnI fragment of the PCR product was ligated to the HindIII-KpnI fragment of pAGE210 above. DH5_a *E. coli* (Clontech) was transformed with the DNA to develop plasmid pAGE-SCGFβ shown in Fig. 17, where abbreviations include; pSE, SV40 early promoter, Hyg; hygromycin resistance gene, dhfr; dihydrofolate reductase gene, P1, pBR322-derived P1 promoter, Ptk, Herpes simplex virus (HSV) thymidine kinase (tk) promoter, SP.BG; rabbit β globin gene splicing signal, ABG, rabbit β globin gene poly(A) addition signal, and ASE; SV40 early gene poly(A) addition signal.

15 (2) Expression of Human SCGF Polypeptide Gene in Animal Cells

The introduction of a plasmid into animal cells was performed by electroporation according to the method of Miyaji et al. (Miyaji et al., Cytotechnology, 3, 133-140, 1990). pAGE-SCGFβ 4 µg obtained in (1) above was introduced into 20 4x10⁶ dhfr gene-deleted CHO cells (Urlaub and Chasin, Proc. Natl. Acad. Sci. USA, 77, 4216-4220, 1980). The cells were suspended in MEMα 2000-dFCS(5) 10 ml [MEMα 2000 medium (GIBCO/BRL) containing 5% dFCS, 1/40 volume of 7.5% NaHCO₃, 3% L-glutamine solution (200 mM; GIBCO/BRL), 0.5% penicillin/streptomycin solution (GIBCO/BRL; 500 units/ml penicillin and 5000 µg/ml streptomycin)], and incubated in 10-cm plates (Iwaki Glass) at 37°C under 5% CO₂ in air for 24 hours. Hygromycin (GIBCO/BRL) was added at a concentration of 0.3 mg/ml, and the cells were cultured for 1 to 2 weeks. Transformed cells were harvested at the time of confluence, suspended in MEMα 2000-dFCS(5) containing 0.3 mg/ml hygromycin and 50 nM methotrexate (MTX) at a density of 1-2x10⁵/ml, and distributed into F75 flasks (Greiner) by 2-ml aliquots. After 1 to 2-week culture, 50 nM MTX-resistant clones were suspended in MEMα 25 2000-dFCS(5) containing 0.3 mg/ml hygromycin and 200 nM MTX at a density of 1-2x10⁵/ml, distributed into F75 flasks by 2-ml aliquots. After another 1 to 2 week culture, 200 nM MTX-resistant clones were suspended in MEMα 2000-dFCS(5) containing 200 nM MTX at a density of 1-2x10⁵/ml, distributed into F75 flasks by 15 ml aliquots, and further cultured for 5-7 days. When the resistant clones became 80-100% confluent, the medium was exchanged with a serum-free medium for CHO cells 15 ml (EX-cell 301 medium from JRH Biosciences). After 4-day culture, culture supernatants containing SCGF polypeptide were harvested by centrifugation.

35 (3) Preparation of Anti-SCGF Polyclonal Antibody

An origo peptide Ac-Arg-Glu-Trp-Glu-Gly-Gly-Trp-Gly-Gly-Ala-Gln-Glu-Glu-Arg-Glu-Arg-Glu-Ala-Leu-Cys ("Ac-Arg" indicates acetylarginine) corresponding to the amino acids at position 27-46 From the SCGF polypeptide (SEQ ID NO: 1) was solidphase-synthesized by the Fmoc method (Fields and Noble, Int. J. Peptide Protein Res., 35: 161-40 214, 1990) using a Shimadzu automatic peptidesynthesizer Model PSSM-8 according to the manufacturer's synthesis program.

The synthetic peptide was crosslinked to Keyhole Lympet hemocyanin(KLH;Calbiochem) using m-maleimide-benzoyl-n-hydroxysuccyl (MBS; Nacalai Tesque) to improve its immunogenicity. Cys at the C-terminal of the synthetic peptide was favorable in reaction with MBS. One tenth volume of MBS was added dropwise to 10mg/ml KLH in PBS, and agitated at room temperature for 30 minutes. Free MBS was removed through a Sephadex G-25 column pre-equilibrated with PBS. KLH-MBS 2.5mg was mixed with the synthetic peptide 1mg in 0.1 M phosphate buffer, agitated at room temperature for 3 hours, and dialyzed against PBS containing 0.5 M NaCl. Five-week old female SD rats were immunized with the KLH-peptide 100 µg plus aluminium gel 2mg and 1x10⁹ pertussis vaccine(ChibaPre.Serum Institute). Two weeks thereafter, the KLH-peptide 100 µg alone was administered once aweek 4 times in total. Three days after the final boost, whole blood was obtained to prepare a polyclonal antibody.

50 (4) Western Blotting

The CHO culture supernatants obtained in (2) above was fractionated by sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE), and transferred Immobilon Transfer Membrane (Millipore) by the semi-dry blotting method. It was soaked in advance 100% methanol for 20 seconds,then in a solution containing 10 mM CAPS, 10% methanol and 0.03% SDS(pH 11.0)for over 30 minutes. After blotting at 2mA/cm² for 2 hours, the membrane was shaken in a blocking solution 200 ml/PBS buffer (137 mM NaCl, 2.7mM KCl, 9.6mM Na₂ HPO₄ KH₂PO₄)(pH 7.2)con-

taining 1% BSA) for 1 hour and washed once with PBS. The membrane was placed in a vinyl bag together with 1:500-diluted anti-SCGF polyclonal antibody (antiserum) prepared in (3) above. The bag was sealed and shaken at room temperature for 2-3 hours. Subsequently, the membrane was washed twice with 0.05% Tween 20-containing PBS for 5 minutes and once with PBS for 5 minutes. It was soaked in PBS 4ml containing 0.65 g/ml peroxidase-labelled anti-rat IgG antibody (anti-rat immunoglobulin 1.3 g /liter; DAKO-immunoglobulins a/s) (i.e. 1:2000-diluted secondary antibody) and placed in a vinyl bag. The bag was sealed and shaken at room temperature for 1 hour. The membrane was washed twice with 0.05% Tween 20-containing PBS for 5 minutes and once with PBS for 5 minutes. Antibody-bound proteins were chemiluminescently analyzed using ECL Western Blotting Detection Reagents (Amersham). A specific band was detected at around 43 kDa.

(5) Purification of SCGF from the CHO Cell Culture Supernatants

First Step: Ammonium Sulfate Precipitation Ammonium sulfate 17.25g was added to the CHO cell culture supernatants 98ml obtained in (2) above (30% ammonium sulfate at final concentration), agitated, and left at 4°C for 2 hours. The solution was centrifuged at 18800 G for 30 minutes. Ammonium sulfate 13.44g was added to the supernatant (50% ammonium sulfate at final concentration), agitated, and left at 4°C for 2 hours. The solution was centrifuged at 18800 G for 30 minutes. The precipitates were dissolved in 0.5 M NaCl-containing 20 mM sodium phosphate buffer (pH 7.2) 9ml and purified by Zn²⁺ chelating-Sepharose chromatography.

Second Step: Zn²⁺ Chelating-Sepharose Chromatography

The precipitates obtained in the first step was applied to a Zn²⁺ chelating-Sepharose Fast Flow column (5 mm x 50 mm; Pharmacia) equilibrated with 0.5 M NaCl-containing 20 mM sodium phosphate buffer (pH 7.2), washed thoroughly with the same buffer, and eluted with a linear histidine gradient (0-0.25 M). The eluted fractions were assayed for antibody binding activity as shown in (4) above. The fractions eluted with 0.06 M-0.15 M histidine exhibited a specific antibody.

Third Step: MonoQ Anion Exchange Chromatography

The active fractions obtained in the second step were concentrated with Centricon-10 ultrafiltration membrane (Millipore). It was diluted with 10 volumes of 10 mM Tris-HCl (pH 7.0), applied to a MonoQ PC1.6/5 column (1.6 mm x 50 mm; Pharmacia) equilibrated with 10 mM Tris-HCl (pH 7.0), washed thoroughly with the same buffer, and eluted with a linear NaCl gradient (0-1 M). The eluted fractions were assayed for antibody binding activity as shown in (4) above. The fractions eluted at about 0.5 M NaCl exhibited a specific activity. The active fraction was subjected to SDS-PAGE under reducing condition with 2-ME and silver stained (2D-Silver Staining Reagent-II "Daiichi"; Daiichi Pure Chemical). A band was detected at around 43 kDa as shown at lane 2 in Fig. 18; Lane 1 is a molecular weight marker; numerals represent molecular sizes. An arrow indicates the purified human SCGF.

(6) Structural Analysis of the SCGF Purified from the CHO Cell Culture Supernatants

The N-terminal amino acid sequence of the purified SCGF was analyzed by conventional methods. Briefly, the purified fraction obtained in (5) above was subjected to SDS-PAGE under reducing condition with 2-ME and electrically transferred to a PVDF membrane (ProBlott; Perkin Elmer) according to the method of P. Matsudaira (J.B. C., 262, 40 10035-10038, 1987). The membrane was stained with Coomassie Brilliant Blue, and a band around 43 kDa positive in the Western blotting shown in (4) above was cut out. The N-terminal amino acid sequence of the band was analyzed with a gas phase protein sequencer (Procise Mode 1494; Perkin Elmer) according to the manufacturer's instructions. The amino acid sequence (SEQ ID NO: 16) was compatible with the amino acids from position 22 (from the N-terminus) of the amino acid sequence (SEQ ID NO: 1) deduced from the SCGF nucleotide sequence.

Effect of the Invention

The present invention provides a novel polypeptide possessing growth activities on hematopoietic stem cells, a gene encoding the polypeptide and an antibody reacting specifically with the polypeptide, as well as a method for isolating the above gene and a vector for use in the method.

Brief Description of the Drawings

- Fig. 1: a diagram showing an outline of cDNA synthesis.
- Fig. 2: a diagram illustrating the process for constructing CDMflit.
- Fig. 3: a diagram illustrating the process for constructing SHDM.
- Fig. 4: a diagram illustrating the processes for constructing λ CDM and λ SHDM.
- Fig. 5: graphs showing the activities of the polypeptide of the invention expressed in COS-1 cells.

EP 0 860 447 A1

- Fig. 6: graphs showing the activities of the polypeptide of the invention produced by KPB-M15 cells.
Fig. 7: a diagram illustrating the construction of expression vector for GST/116-10C fusion protein.
Fig. 8: a graph showing the neutralizing effect of anti-SCGF monoclonal antibody on the activities of the polypeptide of the invention.
5 Fig. 9: a graph showing fractionation of the polypeptide of the invention through DEAE-Sephadex.
Fig. 10: a graph showing fractionation of the polypeptide of the invention through Octyl-Sephadex.
Fig. 11: a graph showing fractionation of the polypeptide of the invention through Cu²⁺ chelating-Sephadex.
Fig. 12: a graph showing fractionation of the polypeptide of the invention through ConA-Sephadex.
10 Fig. 13: a graph showing fractionation of the polypeptide of the invention through WGA-agarose.
Fig. 14: a graph showing fractionation of the polypeptide of the invention through Blue-Sephadex.
Fig. 15: a graph showing fractionation of the polypeptide of the invention through Red-Sephadex.
Fig. 16: a graph showing fractionation of the polypeptide of the invention through Sephadex S-200HR.
Fig. 17: a diagram illustrating the process for constructing pAGE-SCGF β .
Fig. 18: SDS-PAGE pattern of a purified culture supernatant of CHO cells expressing human SCGF.

15

20

25

30

35

40

45

50

55

SEQUENCE LISTING

5 SEQ ID NO: 1
SEQUENCE LENGTH: 245
10 SEQUENCE TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
15 SEQUENCE DESCRIPTION:
Met Gln Ala Ala Trp Leu Leu Gly Ala Leu Val Val Pro Gln Leu Leu
1 5 10 15
20 Gly Phe Gly His Gly Ala Arg Gly Ala Glu Arg Glu Trp Glu Gly Gly
20 25 30
Trp Gly Gly Ala Gln Glu Glu Glu Arg Glu Arg Glu Ala Leu Met Leu
25 35 40 45
Lys His Leu Gln Glu Ala Leu Gly Leu Pro Ala Gly Arg Gly Asp Glu
30 50 55 60
Asn Pro Ala Gly Thr Val Glu Gly Lys Glu Asp Trp Glu Met Glu Glu
35 65 70 75 80
Asp Gln Gly Glu Glu Glu Glu Glu Ala Thr Pro Thr Pro Ser Ser
35 85 90 95
Gly Pro Ser Pro Ser Pro Thr Pro Glu Asp Ile Val Thr Tyr Ile Leu
40 100 105 110
Gly Arg Leu Ala Gly Leu Asp Ala Gly Leu His Gln Leu His Val Arg
45 115 120 125
Leu His Ala Leu Asp Thr Arg Val Val Glu Leu Thr Gln Gly Leu Arg
50 130 135 140
Gln Leu Arg Asn Ala Ala Gly Asp Thr Arg Asp Ala Val Gln Ala Leu
55 145 150 155 160
Gln Glu Ala Gln Gly Arg Ala Glu Arg Glu His Gly Arg Leu Glu Gly

EP 0 860 447 A1

165 170 175
5 Cys Leu Lys Gly Leu Arg Leu Gly His Lys Cys Phe Leu Leu Ser Arg
180 185 190
Asp Phe Glu Ala Gln Pro Ser Ala Ser Pro His Pro Leu Ser Pro Asp
10 195 200 205
Gln Pro Asn Gly Gly Thr Leu Glu Asn Cys Val Ala Gln Ala Ser Asp
210 215 220
15 Asp Gly Ser Trp Trp Asp His Asp Cys Gln Arg Arg Leu Tyr Tyr Val
225 230 235 240
Cys Glu Phe Pro Phe
20 245

25 SEQ ID NO: 2

SEQUENCE LENGTH: 1196

SEQUENCE TYPE: nucleic acid

30 STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: cDNA to mRNA

35 ORIGINAL SOURCE:

ORGANISM: *Homo sapiens*

40 TISSUE TYPE: peripheral blood leukocytes

CELL TYPE: myeloid blast cells

CELL LINE: KPB-M15

IMMEDIATE SOURCE:

45 LIBRARY: λ SHDM (KPB)

CLONE: 116-10C

BIOLOGICAL ACTIVITY:

50 erythroid burst-promoting activity (BPA)

granulocyte macrophage colony-promoting activity (GPA)

55

EP 0 860 447 A1

FEATURE:

NAME/KEY: polyA signal

LOCATION: 1097..1102

IDENTIFICATION METHOD: S

NAME/KEY: polyA site

LOCATION: 1129

IDENTIFICATION METHOD: E

SEQUENCE DESCRIPTION:

GAGAGAAGCT GGGAGAATCG GGAACCTGGG GGCTAGTGAC CTGCACACAG GGCAGGGCA 60

CTCGGCAGTT CCCAGAGGCC ACCCCTCCCA CCCCAGACAT CCAGACATCT GGAACTTTGG 120

GTGCCAAGAG TCCAGCTTA 139

ATG CAG GCA GCC TGG CTT TTG GGG GCT TTG GTG GTC CCC CAG CTC TTG 187

Met Gln Ala Ala Trp Leu Leu Gly Ala Leu Val Val Pro Gln Leu Leu

1 5 10 15

GGC TTT GGC CAT GGG GCT CGG GGA GCA GAG AGG GAG TGG GAG GGA GGC 235

Gly Phe Gly His Gly Ala Arg Gly Ala Glu Arg Glu Trp Glu Gly Gly

30 20 25 30

TGG GGA GGT GCC CAG GAG GAG CGG GAG AGG GAG GCC CTG ATG CTG 283

Trp Gly Gly Ala Gln Glu Glu Glu Arg Glu Arg Glu Ala Leu Met Leu

35 40 45

AAG CAT CTG CAG GAA GCC CTA GGA CTG CCT GCT GGG AGG GGG GAT GAG 331

Lys His Leu Gln Glu Ala Leu Gly Leu Pro Ala Gly Arg Gly Asp Glu

40 50 55 60

AAT CCT GCC GGA ACT GTT GAG GGA AAA GAG GAC TGG GAG ATG GAG GAG 379

Asn Pro Ala Gly Thr Val Glu Gly Lys Glu Asp Trp Glu Met Glu Glu

45 65 70 75 80

GAC CAG GGG GAG GAA GAG GAG GAA GCA ACG CCA ACC CCA TCC TCC 427

Asp Gln Gly Glu Glu Glu Glu Glu Ala Thr Pro Thr Pro Ser Ser

50 85 90 95

55

EP 0 860 447 A1

	GGC CCC AGC CCC TCT CCC ACC CCT GAG GAC ATC GTC ACT TAC ATC CTG	475		
	Gly Pro Ser Pro Ser Pro Thr Pro Glu Asp Ile Val Thr Tyr Ile Leu			
5	100	105	110	
	GGC CGC CTG GCC GGC CTG GAC GCA GGC CTG CAC CAG CTG CAC GTC CGT	523		
	Gly Arg Leu Ala Gly Leu Asp Ala Gly Leu His Gln Leu His Val Arg			
10	115	120	125	
	CTG CAC GCG TTG GAC ACC CGC GTG GTC GAG CTG ACC CAG GGG CTG CGG	571		
	Leu His Ala Leu Asp Thr Arg Val Val Glu Leu Thr Gln Gly Leu Arg			
15	130	135	140	
	CAG CTG CGG AAC GCG GCA GGC GAC ACC CGC GAT GCC GTG CAA GCC CTG	619		
	Gln Leu Arg Asn Ala Ala Gly Asp Thr Arg Asp Ala Val Gln Ala Leu			
20	145	150	155	160
	CAG GAG GCG CAG GGT CGC GCC GAG CGC GAG CAC GGC CGC TTG GAG GGC	667		
	Gln Glu Ala Gln Gly Arg Ala Glu Arg Glu His Gly Arg Leu Glu Gly			
25	165	170	175	
	TGC CTG AAG GGG CTG CGC CTG GGC CAC AAG TGC TTC CTG CTC TCG CGC	715		
	Cys Leu Lys Gly Leu Arg Leu Gly His Lys Cys Phe Leu Leu Ser Arg			
30	180	185	190	
	GAC TTC GAA GCC CAG CCC AGC GCC TCG CCG CAT CCG CTC AGC CCG GAC	763		
	Asp Phe Glu Ala Gln Pro Ser Ala Ser Pro His Pro Leu Ser Pro Asp			
35	195	200	205	
	CAG CCC AAC GGT GGC ACG CTC GAG AAC TGC GTG GCG CAG GCC TCT GAC	811		
	Gln Pro Asn Gly Gly Thr Leu Glu Asn Cys Val Ala Gln Ala Ser Asp			
40	210	215	220	
	GAC GGC TCC TGG TGG GAC CAC GAC TGC CAG CGG CGT CTC TAC TAC GTC	859		
	Asp Gly Ser Trp Trp Asp His Asp Cys Gln Arg Arg Leu Tyr Tyr Val			
45	225	230	235	240
	TGC GAG TTC CCC TTC	874		
	Cys Glu Phe Pro Phe			
50				
55				

245

5 TAGGGGGGCC GGTACCCCGC CTCCCTGCCA ATCCCACCAAC CCGGCCTTTC CCTGCGCCGT 934
GCCCACCCCTC CTCCGGAATC TCCCTCCCT TCCTGGCCAC GAATGGCAGC GTCCTCCCCG 994
ACCCCCAGTC TGGGCGCTTC TGGGAGGGCT CTTGCGGTGC CGGCACTCCT CCTTGTTAGT 1054
10 GTCTTCCTT GAAGGGGCGG GCACCAGGCT AGGTCCGGTG CCAATAAAATC CTTGTGGAAT 1114
CTGACTTGAG GGGAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 1174
AAAAAAAAAA AAAAAAAAAA AA 1196

15

SEQ ID NO: 3

SEQUENCE LENGTH: 45

20

SEQUENCE TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

25

MOLECULE TYPE: other nucleic acid (synthetic DNA)

SEQUENCE DESCRIPTION:

GATATCTTCC AGTTTGGAAC AAGAGTCCAC TATTAAGAA CGTGG

30

SEQ ID NO: 4

SEQUENCE LENGTH: 323

35

SEQUENCE TYPE: amino acid

TOPOLOGY: linear

40

MOLECULE TYPE: protein

SEQUENCE DESCRIPTION:

Met Gln Ala Ala Trp Leu Leu Gly Ala Leu Val Val Pro Gln Leu Leu

45 1 5 10 15

Gly Phe Gly His Gly Ala Arg Gly Ala Glu Arg Glu Trp Glu Gly Gly

20 25 30

50

Trp Gly Gly Ala Gln Glu Glu Arg Glu Arg Glu Ala Leu Met Leu

35 40 45

55

EP 0 860 447 A1

Lys His Leu Gln Glu Ala Leu Gly Leu Pro Ala Gly Arg Gly Asp Glu
5 50 55 60
Asn Pro Ala Gly Thr Val Glu Gly Lys Glu Asp Trp Glu Met Glu Glu
65 65 70 75 80
Asp Gln Gly Glu Glu Glu Glu Ala Thr Pro Thr Pro Ser Ser
10 10 85 90 95
Gly Pro Ser Pro Ser Pro Thr Pro Glu Asp Ile Val Thr Tyr Ile Leu
15 100 105 110
Gly Arg Leu Ala Gly Leu Asp Ala Gly Leu His Gln Leu His Val Arg
115 120 125
Leu His Ala Leu Asp Thr Arg Val Val Glu Leu Thr Gln Gly Leu Arg
20 130 135 140
Gln Leu Arg Asn Ala Ala Gly Asp Thr Arg Asp Ala Val Gln Ala Leu
25 145 150 155 160
Gln Glu Ala Gln Gly Arg Ala Glu Arg Glu His Gly Arg Leu Glu Gly
165 170 175
30 Cys Leu Lys Gly Leu Arg Leu Gly His Lys Cys Phe Leu Leu Ser Arg
180 185 190
Asp Phe Glu Ala Gln Ala Ala Gln Ala Arg Cys Thr Ala Arg Gly
35 195 200 205
Gly Ser Leu Ala Gln Pro Ala Asp Arg Gln Gln Met Glu Ala Leu Thr
40 210 215 220
Arg Tyr Leu Arg Ala Ala Leu Ala Pro Tyr Asn Trp Pro Val Trp Leu
225 230 235 240
45 Gly Val His Asp Arg Arg Ala Glu Gly Leu Tyr Leu Phe Glu Asn Gly
245 250 255
Gln Arg Val Ser Phe Phe Ala Trp His Arg Ser Pro Arg Pro Glu Leu
50 260 265 270
Gly Ala Gln Pro Ser Ala Ser Pro His Pro Leu Ser Pro Asp Gln Pro

EP 0 860 447 A1

275 280 285

Asn Gly Gly Thr Leu Glu Asn Cys Val Ala Gln Ala Ser Asp Asp Gly

290 295 300

Ser Trp Trp Asp His Asp Cys Gln Arg Arg Leu Tyr Tyr Val Cys Glu

305 310 315 320

Phe Pro Phe

323

15

SEQ ID NO: 5

SEQUENCE LENGTH: 969

20 SEQUENCE TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

25 MOLECULE TYPE: cDNA to mRNA

ORIGINAL SOURCE:

30 ORGANISM: *Homo sapiens*

35 TISSUE TYPE: bone marrow

SEQUENCE DESCRIPTION:

35 ATG CAG GCA GCC TGG CTT TTG GGG GCT TTG GTG GTC CCC CAG CTC TTG 48

Met Gln Ala Ala Trp Leu Leu Gly Ala Leu Val Val Pro Gln Leu Leu

40 1 5 10 15

45 GGC TTT GGC CAT GGG GCT CGG GGA GCA GAG AGG GAG TGG GAG GGA GGC 96

Gly Phe Gly His Gly Ala Arg Gly Ala Glu Arg Glu Trp Glu Gly Gly

50 20 25 30

55 TGG GGA GGT GCC CAG GAG GAG CGG GAG AGG GAG GCC CTG ATG CTG 144

Trp Gly Gly Ala Gln Glu Glu Arg Glu Arg Glu Ala Leu Met Leu

60 35 40 45

65 AAG CAT CTG CAG GAA GCC CTA GGA CTG CCT GCT GGG AGG GGG GAT GAG 192

Lys His Leu Gln Glu Ala Leu Gly Leu Pro Ala Gly Arg Gly Asp Glu

55

EP 0 860 447 A1

	50	55	60	
5	AAT CCT GCC GGA ACT GTT GAG GGA AAA GAG GAC TGG GAG ATG GAG GAG			240
	Asn Pro Ala Gly Thr Val Glu Gly Lys Glu Asp Trp Glu Met Glu Glu			
10	65	70	75	80
	GAC CAG GGG GAG GAA GAG GAG GAG GAA GCA ACG CCA ACC CCA TCC TCC			288
	Asp Gln Gly Glu Glu Glu Glu Glu Ala Thr Pro Thr Pro Ser Ser			
15	85	90	95	
	GGC CCC AGC CCC TCT CCC ACC CCT GAG GAC ATC GTC ACT TAC ATC CTG			336
	Gly Pro Ser Pro Ser Pro Thr Pro Glu Asp Ile Val Thr Tyr Ile Leu			
20	100	105	110	
	GGC CGC CTG GCC GGC CTG GAC GCA GGC CTG CAC CAG CTG CAC GTC CGT			384
	Gly Arg Leu Ala Gly Leu Asp Ala Gly Leu His Gln Leu His Val Arg			
25	115	120	125	
	CTG CAC GCG TTG GAC ACC CGC GTG GTC GAG CTG ACC CAG GGG CTG CGG			432
	Leu His Ala Leu Asp Thr Arg Val Val Glu Leu Thr Gln Gly Leu Arg			
30	130	135	140	
	CAG CTG CGG AAC GCG GCA GGC GAC ACC CGC GAT GCC GTG CAA GCC CTG			480
	Gln Leu Arg Asn Ala Ala Gly Asp Thr Arg Asp Ala Val Gln Ala Leu			
35	145	150	155	160
	CAG GAG GCG CAG GGT CGC GCC GAG CGC GAG CAC GGC CGC TTG GAG GGC			528
	Gln Glu Ala Gln Gly Arg Ala Glu Arg Glu His Gly Arg Leu Glu Gly			
40	165	170	175	
	TGC CTG AAG GGG CTG CGC CTG GGC CAC AAG TGC TTC CTG CTC TCG CGC			576
	Cys Leu Lys Gly Leu Arg Leu Gly His Lys Cys Phe Leu Leu Ser Arg			
45	180	185	190	
	GAC TTC GAA GCT CAG GCG GCG CAG GCG CGG TGC ACG GCG CGG GGC			624
	Asp Phe Glu Ala Gln Ala Ala Gln Ala Arg Cys Thr Ala Arg Gly			
50	195	200	205	
	GGG AGC CTG GCG CAG CCG GCA GAC CGC CAG CAG ATG GAG GCG CTC ACT			672

EP 0 860 447 A1

Gly Ser Leu Ala Gln Pro Ala Asp Arg Gln Gln Met Glu Ala Leu Thr
210 215 220
5 CGG TAC CTG CGC GCG GCG CTC GCT CCC TAC AAC TGG CCC GTG TGG CTG 720
Arg Tyr Leu Arg Ala Ala Leu Ala Pro Tyr Asn Trp Pro Val Trp Leu
10 225 230 235 240
GGC GTG CAC GAT CGG CGC GCC GAG GGC CTC TAC CTC TTC GAA AAC GGC 768
Gly Val His Asp Arg Arg Ala Glu Gly Leu Tyr Leu Phe Glu Asn Gly
15 245 250 255
CAG CGC GTG TCC TTC GCC TGG CAT CGC TCA CCC CGC CCC GAG CTC 816
Gln Arg Val Ser Phe Phe Ala Trp His Arg Ser Pro Arg Pro Glu Leu
20 260 265 270
GGC GCC CAG CCC AGC GCC TCG CCG CAT CCG CTC AGC CCG GAC CAG CCC 864
Gly Ala Gln Pro Ser Ala Ser Pro His Pro Leu Ser Pro Asp Gln Pro
25 275 280 285
AAC GGT GGC ACG CTC GAG AAC TGC GTG GCG CAG GCC TCT GAC GAC GGC 912
Asn Gly Gly Thr Leu Glu Asn Cys Val Ala Gln Ala Ser Asp Asp Gly
30 290 295 300
TCC TGG TGG GAC CAC GAC TGC CAG CGG CGT CTC TAC TAC GTC TGC GAG 960
Ser Trp Trp Asp His Asp Cys Gln Arg Arg Leu Tyr Tyr Val Cys Glu
35 305 310 315 320
TTC CCC TTC
40 Phe Pro Phe 969
323

45 SEQ ID NO: 6
SEQUENCE LENGTH: 21
SEQUENCE TYPE: nucleic acid
50 STRANDEDNESS: single
TOPOLOGY: linear

65

EP 0 860 447 A1

MOLECULE TYPE: other nucleic acid (synthetic DNA)

SEQUENCE DESCRIPTION:

5 GAGTCCAGCT TAATGCAGGC A

10 SEQ ID NO: 7

SEQUENCE LENGTH: 21

SEQUENCE TYPE: nucleic acid

15 STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: other nucleic acid (synthetic DNA)

20 SEQUENCE DESCRIPTION:

CTAGAAGGGG AACTCGCAGA C

25 SEQ ID NO: 8

SEQUENCE LENGTH: 328

SEQUENCE TYPE: amino acid

30 TOPOLOGY: linear

MOLECULE TYPE: protein

35 SEQUENCE DESCRIPTION:

Met Gln Ala Ala Trp Leu Leu Gly Ala Leu Val Val Pro Gln Leu Leu

1 5 10 15

40 Ser Phe Gly His Gly Ala Arg Gly Pro Gly Arg Glu Trp Glu Gly Gly

20 25 30

Trp Gly Gly Ala Leu Glu Glu Glu Arg Glu Arg Glu Ser Gln Met Leu

45 35 40 45

Lys Asn Leu Gln Glu Ala Leu Gly Leu Pro Thr Gly Val Gly Asn Glu

50 55 60

55 Asp Asn Leu Ala Glu Asn Pro Glu Asp Lys Glu Val Trp Glu Thr Thr

65 70 75 80

55

EP 0 860 447 A1

Glu Thr Gln Gly Glu Glu Glu Glu Glu Ile Thr Thr Ala Pro Ser
85 90 95
5 Ser Ser Pro Asn Pro Phe Pro Ser Pro Ser Pro Thr Pro Glu Asp Thr
100 105 110
10 Val Thr Tyr Ile Leu Gly Arg Leu Ala Ser Leu Asp Ala Gly Leu His
115 120 125
15 Gln Leu His Val Arg Leu His Val Leu Asp Thr Arg Val Val Glu Leu
130 135 140
20 Thr Gln Gly Leu Arg Gln Leu Arg Asp Ala Ala Ser Asp Thr Arg Asp
145 150 155 160
25 Ser Val Gln Ala Leu Lys Glu Val Gln Asp Arg Ala Glu Gln Glu His
165 170 175
30 Gly Arg Leu Glu Gly Cys Leu Lys Gly Leu Arg Leu Gly His Lys Cys
180 185 190
35 Phe Leu Leu Ser Arg Asp Phe Glu Thr Gln Ala Ala Ala Gln Ala Arg
195 200 205
40 Cys Lys Ala Arg Gly Gly Ser Leu Ala Gln Pro Ala Asp Arg Gln Gln
210 215 220
45 Met Asp Ala Leu Ser Arg Tyr Leu Arg Ala Ala Leu Ala Pro Tyr Asn
225 230 235 240
50 Trp Pro Val Trp Leu Gly Val His Asp Arg Arg Ser Glu Gly Leu Tyr
245 250 255
55 Leu Phe Glu Asn Gly Gln Arg Val Ser Phe Phe Ala Trp His Arg Ala
260 265 270
60 Phe Ser Leu Glu Ser Gly Ala Gln Pro Ser Ala Ala Thr His Pro Leu
275 280 285
65 Ser Pro Asp Gln Pro Asn Gly Gly Val Leu Glu Asn Cys Val Ala Gln
290 295 300
70 Ala Ser Asp Asp Gly Ser Trp Trp Asp His Asp Cys Glu Arg Arg Leu

EP 0 860 447 A1

305

310

315

320

5 Tyr Phe Val Cys Glu Phe Pro Phe

325

328

10 SEQ ID NO: 9

SEQUENCE LENGTH: 1399

SEQUENCE TYPE: nucleic acid

15 STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: cDNA to mRNA

20 ORIGINAL SOURCE:

ORGANISM: mouse

TISSUE TYPE: calvaria

25 CELL TYPE: stromal cells

CELL LINE: MC3T3-G2/PA6

IMMEDIATE SOURCE:

30 LIBRARY: AMoPR (PA6)

CLONE: 21-1C4-5H6

35 SEQUENCE DESCRIPTION:

GAAGCTGGCA GAAGAAGGTC AAGGGGCTTG TGAGCTGCC ACCAGACTGG GACACTTGCT 60

AGGTCTATAC AGCAGTCCTA CCCCTGGCAT TCTGACCTCT CTACTATTG GGTGCTGGGA 120

40 AGCCCAGCTG G 131

ATG CAG GCA GCC TGG CTC TTG GGG GCC CTA GTG GTC CCT CAG CTT TTG 179

Met Gln Ala Ala Trp Leu Leu Gly Ala Leu Val Val Pro Gln Leu Leu

45 1 5 10 15

AGT TTT GGT CAT GGA GCC CGA GGT CCT GGG AGG GAG TGG GAG GGA GGC 227

Ser Phe Gly His Gly Ala Arg Gly Pro Gly Arg Glu Trp Glu Gly Gly

50 20 25 30

TGG GGA GGT GCC CTG GAG GAG AGA GAG CGG GAG TCA CAG ATG TTG 275

55

EP 0 860 447 A1

	Trp Gly Gly Ala Leu Glu Glu Glu Arg Glu Arg Glu Ser Gln Met Leu				
5	35	40	45		
	AAG AAT CTC CAG GAG GCC CTA GGG CTG CCC ACT GGG GTG GGA AAT GAG			323	
	Lys Asn Leu Gln Glu Ala Leu Gly Leu Pro Thr Gly Val Gly Asn Glu				
10	50	55	60		
	GAT AAT CTT GCT GAA AAC CCT GAA GAC AAA GAG GTC TGG GAG ACC ACA			371	
	Asp Asn Leu Ala Glu Asn Pro Glu Asp Lys Glu Val Trp Glu Thr Thr				
15	65	70	75	80	
	GAG ACT CAA GGG GAA GAA GAG GAA GAG GAA ATC ACC ACA GCA CCT TCT			419	
	Glu Thr Gln Gly Glu Glu Glu Glu Glu Ile Thr Thr Ala Pro Ser				
20	85	90	95		
	TCT AGT CCC AAC CCT TTC CCC AGC CCT TCT CCC ACA CCA GAG GAC ACT			467	
	Ser Ser Pro Asn Pro Phe Pro Ser Pro Ser Pro Thr Pro Glu Asp Thr				
25	100	105	110		
	GTC ACT TAC ATC TTG GGC CGC TTG GCC AGC CTC GAT GCA GGC CTA CAC			515	
	Val Thr Tyr Ile Leu Gly Arg Leu Ala Ser Leu Asp Ala Gly Leu His				
30	115	120	125		
	CAA TTG CAC GTC CGT CTG CAC GTT TTG GAC ACC CGT GTG GTT GAG CTG			563	
	Gln Leu His Val Arg Leu His Val Leu Asp Thr Arg Val Val Glu Leu				
35	130	135	140		
	ACC CAG GGG CTG CGG CAG CTG CGG GAT GCT GCG AGT GAC ACC CGC GAC			611	
	Thr Gln Gly Leu Arg Gln Leu Arg Asp Ala Ala Ser Asp Thr Arg Asp				
40	145	150	155	160	
	TCA GTG CAA GCC CTG AAG GAG GTC CAG GAC CGT GCT GAG CAG GAG CAC			659	
	Ser Val Gln Ala Leu Lys Glu Val Gln Asp Arg Ala Glu Gln Glu His				
45	165	170	175		
	GGC CGC TTG GAG GGC TGC CTG AAG GGC CTG CGC CTT GGC CAC AAG TGC			707	
	Gly Arg Leu Glu Gly Cys Leu Lys Gly Leu Arg Leu Gly His Lys Cys				
50	180	185	190		

EP 0 860 447 A1

	TTC CTG CTC TCG CGA GAC TTC GAG ACC CAG GCG GCG GCG CAG GCG CGG	755		
	Phe Leu Leu Ser Arg Asp Phe Glu Thr Gln Ala Ala Ala Gln Ala Arg			
5	195	200	205	
	TGC AAG GCG CGA GGT GGG AGC TTA GCA CAG CCT GCG GAC CGC CAG CAA	803		
	Cys Lys Ala Arg Gly Gly Ser Leu Ala Gln Pro Ala Asp Arg Gln Gln			
10	210	215	220	
	ATG GAT GCG CTA AGC CGG TAC TTA CGC GCC GCT CTC GCC CCC TAC AAC	851		
15	Met Asp Ala Leu Ser Arg Tyr Leu Arg Ala Ala Leu Ala Pro Tyr Asn			
	225	230	235	240
	TGG CCG GTG TGG CTG GGA GTG CAC GAT CGG CGC TCC GAG GGG CTC TAC	899		
20	Trp Pro Val Trp Leu Gly Val His Asp Arg Arg Ser Glu Gly Leu Tyr			
	245	250	255	
	CTT TTC GAG AAC GGC CAG CGC GTG TCT TTC TTC GCC TGG CAC CGC GCA	947		
25	Leu Phe Glu Asn Gly Gln Arg Val Ser Phe Phe Ala Trp His Arg Ala			
	260	265	270	
	TTC AGC CTG GAG TCC GGC GCC CAG CCT AGT GCG GCA ACA CAT CCA CTC	995		
30	Phe Ser Leu Glu Ser Gly Ala Gln Pro Ser Ala Ala Thr His Pro Leu			
	275	280	285	
	AGC CCG GAT CAG CCC AAT GGC GGC GTC CTG GAG AAC TGC GTG GCC CAG	1043		
35	Ser Pro Asp Gln Pro Asn Gly Gly Val Leu Glu Asn Cys Val Ala Gln			
	290	295	300	
	GCC TCA GAC GAC GGT TCT TGG TGG GAC CAT GAC TGT GAG CGG CGC CTC	1091		
40	Ala Ser Asp Asp Gly Ser Trp Trp Asp His Asp Cys Glu Arg Arg Leu			
	305	310	315	320
45	TAC TTC GTC TGC GAG TTC CCC TTC	1115		
	Tyr Phe Val Cys Glu Phe Pro Phe			
	325	328		
50	TAGAGAACCG GTCTCTGCC AGGAGCTCTA GTGCACATTG TGCACCGTAC ACCGCGCACC	1175		
	CTATTGTTAG GGGCCTGGGA GTCGCTCAGA GATTAAGCGT GACCATGAAT ACATTTAAT	1235		

55

EP 0 860 447 A1

CAGAAGAGGT TTTTATTTT AGATACTGGC ACCCAGACTG ATTGGGGCCA GGTGTGCTCC 1295
TGAGATTGCT TCCAAGATGC ATTATCAGCC CAGGGATTTT AAAGGCAAAC CCCACAAGAT 1355
5 TGCATGTAGC CTGCTTACAT GTAGGCCCGGA GCATAAAAAT TTAA 1399

10 SEQ ID NO: 10
SEQUENCE LENGTH: 11
SEQUENCE TYPE: nucleic acid
15 STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid (synthetic DNA)
20 SEQUENCE DESCRIPTION:
CTTTAGAGCA C

25 SEQ ID NO: 11
SEQUENCE LENGTH: 8
SEQUENCE TYPE: nucleic acid
30 STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid (synthetic DNA)
35 SEQUENCE DESCRIPTION:
CTCTAAAG

40 SEQ ID NO: 12
SEQUENCE LENGTH: 328
45 SEQUENCE TYPE: amino acid
STRANDEDNESS: linear
TOPOLOGY: linear
50 MOLECULE TYPE: protein
SEQUENCE DESCRIPTION:

EP 0 860 447 A1

Met Gln Ala Ala Trp Leu Leu Gly Ala Leu Leu Val Pro His Leu Leu
1 5 10 15
5 Ser Phe Gly His Gly Ala Arg Gly His Gly Lys Glu Trp Glu Gly Val
20 25 30
Trp Gly Gly Ala Leu Glu Glu Arg Asp Arg Glu Ser Leu Met Leu
10 35 40 45
Lys Asn Leu Gln Glu Ala Leu Gly Leu Pro Thr Gly Val Gly Asn Lys
15 50 55 60
Asp Asn Leu Ala Glu Asn Ser Glu Gly Lys Glu Val Trp Glu Ala Thr
65 70 75 80
20 Glu Thr Gln Gly Glu Glu Glu Glu Glu Thr Thr Thr Pro Ser
85 90 95
Ser Ser Pro Thr Pro Phe Pro Ser Pro Ser Pro Thr Ser Glu Asp Thr
25 100 105 110
Val Thr Tyr Ile Leu Gly Arg Leu Ala Ser Leu Asp Ala Gly Leu His
115 120 125
30 Gln Leu His Ile Arg Leu His Val Leu Asp Thr Arg Val Val Glu Leu
130 135 140
Thr Gln Gly Leu Arg Arg Leu Arg Asp Ala Ala Ser Asp Thr Arg Asp
35 145 150 155 160
Ser Val Gln Ala Leu Lys Glu Val Gln Val Arg Ser Glu Gln Glu His
40 165 170 175
Gly Arg Leu Glu Gly Cys Leu Lys Gly Leu Arg Leu Gly His Lys Cys
180 185 190
45 Phe Leu Leu Ser Arg Asp Phe Glu Thr Gln Ala Ala Ala Gln Ala Arg
195 200 205
Cys Lys Ala Arg Gly Gly Ser Leu Ala Gln Pro Ala Asp Arg Gln Gln
50 210 215 220
Met Asp Ala Leu Ser Arg Tyr Leu Arg Ala Leu Ala Pro Tyr Asn

EP 0 860 447 A1

225 230 235 240
Trp Pro Val Trp Leu Gly Val His Asp Arg Arg Ser Glu Gly Leu Tyr
5 245 250 255
Leu Phe Glu Asn Gly Gln Arg Val Ser Phe Phe Ala Trp His Arg Ala
10 260 265 270
Leu Ser Pro Glu Ser Gly Ala Gln Pro Ser Ala Ala Ser His Pro Leu
15 275 280 285
Ser Pro Asp Gln Pro Asn Gly Gly Ile Leu Glu Asn Cys Val Ala Gln
20 290 295 300
Ala Ser Asp Asp Gly Ser Trp Trp Asp His Asp Cys Glu Arg Arg Leu
25 305 310 315 320
Tyr Phe Val Cys Glu Phe Pro Phe
325 328

26 SEQ ID NO: 13

30 SEQUENCE LENGTH: 984

SEQUENCE TYPE: nucleic acid

STRANDEDNESS: single

35 TOPOLOGY: linear

MOLECULE TYPE: cDNA to mRNA

ORIGINAL SOURCE:

40 ORGANISM: rat

CELL TYPE: osteoblastoma cells

CELL LINE: ROS-17/2.8-5

45 SEQUENCE DESCRIPTION:

ATG CAG GCA GCC TGG CTC TTG GGG GCC CTA CTG GTC CCT CAC CTT TTG 48
Met Gln Ala Ala Trp Leu Leu Gly Ala Leu Leu Val Pro His Leu Leu

60 1 5 10 15

AGT TTT GGC CAT GGA GCC CGA GGT CAT GGG AAG GAA TGG GAA GGA GTC 96

65

EP 0 860 447 A1

Ser Phe Gly His Gly Ala Arg Gly His Gly Lys Glu Trp Glu Gly Val
 20 25 30
 5 TGG GGA GGT GCC CTG GAG GAG CGA GAT CGG GAG TCA CTG ATG TTG 144
 Trp Gly Gly Ala Leu Glu Glu Arg Asp Arg Glu Ser Leu Met Leu
 10 35 40 45
 AAG AAT CTC CAG GAG GCC CTA GGG CTG CCC ACT GGG GTG GGA AAT AAG 192
 Lys Asn Leu Gln Glu Ala Leu Gly Leu Pro Thr Gly Val Gly Asn Lys
 15 50 55 60
 GAT AAT CTT GCT GAA AAC TCT GAA CGC AAA GAG GTC TGG GAG GCC ACG 240
 Asp Asn Leu Ala Glu Asn Ser Glu Gly Lys Glu Val Trp Glu Ala Thr
 20 65 70 75 80
 GAG ACT CAA GGG GAA GAA GAG GAA GAG GAA ACC ACC ACA ACA CCT TCT 288
 Glu Thr Gln Gly Glu Glu Glu Glu Glu Thr Thr Thr Pro Ser
 25 85 90 95
 TCT AGC CCC ACT CCT TTC CCC AGC CCT TCT CCT ACA TCA GAG GAC ACA 336
 Ser Ser Pro Thr Pro Phe Pro Ser Pro Ser Pro Thr Ser Glu Asp Thr
 30 100 105 110
 GTC ACT TAC ATC CTG GGC CGC TTG GCC AGC CTC GAT GCA GGC CTA CAC 384
 Val Thr Tyr Ile Leu Gly Arg Leu Ala Ser Leu Asp Ala Gly Leu His
 35 115 120 125
 CAA TTG CAC ATC CGT CTG CAT GTT TTG GAC ACC CGT GTG GTT GAG CTG 432
 Gln Leu His Ile Arg Leu His Val Leu Asp Thr Arg Val Val Glu Leu
 40 130 135 140
 ACC CAG GGG CTG CGG CGG CTG CGG GAT GCC GCG AGT GAC ACC CGC GAC 480
 Thr Gln Gly Leu Arg Arg Leu Arg Asp Ala Ala Ser Asp Thr Arg Asp
 45 145 150 155 160
 TCA GTG CAA GCT CTG AAG GAG GTA CAG GTC CGT TCT GAG CAG GAG CAC 528
 Ser Val Gln Ala Leu Lys Glu Val Gln Val Arg Ser Glu Gln Glu His
 50 165 170 175
 55

EP 0 860 447 A1

GGC CGC TTG GAG GGC TGC CTG AAG GGC CTG CGC CTA GGC CAC AAA TGC 576
Gly Arg Leu Glu Gly Cys Leu Lys Gly Leu Arg Leu Gly His Lys Cys
5 180 185 190

TTC CTG CTC TCG CGA GAC TTC GAG ACA CAG GCG GCG CAA GCG CGG 624
Phe Leu Leu Ser Arg Asp Phe Glu Thr Gln Ala Ala Ala Gln Ala Arg
10 195 200 205

TGT AAG GCG CGA GGT GGG AGT TTA GCG CAG CCT GCG GAC CGC CAG CAA 672
Cys Lys Ala Arg Gly Ser Leu Ala Gln Pro Ala Asp Arg Gln Gln
15 210 215 220

ATG GAT GCT CTA AGC CGG TAC TTA CGA GCT GCT CTT GCC CCC TAC AAC 720
Met Asp Ala Leu Ser Arg Tyr Leu Arg Ala Ala Leu Ala Pro Tyr Asn
20 225 230 235 240

TGG CCA GTG TGG CTG GGA GTG CAC GAC CGG CGC TCG GAG GGG CTC TAC 768
Trp Pro Val Trp Leu Gly Val His Asp Arg Arg Ser Glu Gly Leu Tyr
25 245 250 255

CTT TTC GAG AAC GGC CAG CGC GTG TCA TTC TTC GCC TGG CAC CGC GCA 816
Leu Phe Glu Asn Gly Gln Arg Val Ser Phe Phe Ala Trp His Arg Ala
30 260 265 270

CTC AGC CCG GAG TCC GGC GCC CAG CCT AGT GCG GCA TCC CAT CCA CTT 864
Leu Ser Pro Glu Ser Gly Ala Gln Pro Ser Ala Ala Ser His Pro Leu
35 275 280 285

AGC CCG GAT CAG CCC AAT GGC GGC ATC CTG GAG AAC TGC GTG GCC CAG 912
Ser Pro Asp Gln Pro Asn Gly Gly Ile Leu Glu Asn Cys Val Ala Gln
40 290 295 300

GCC TCA GAC GAC GGC TCC TGG TGG GAC CAT GAC TGT GAG CGG CGC CTC 960
Ala Ser Asp Asp Gly Ser Trp Trp Asp His Asp Cys Glu Arg Arg Leu
45 305 310 315 320

TAC TTC GTC TGC GAG TTC CCT TTC 984
Tyr Phe Val Cys Glu Phe Pro Phe

325 328

5 SEQ ID NO: 14
SEQUENCE LENGTH: 24
10 SEQUENCE TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
15 MOLECULE TYPE: other nucleic acid (synthetic DNA)
SEQUENCE DESCRIPTION:
ATTTGGGTGC TGGGAACCCC AGCT

20 SEQ ID NO: 15
SEQUENCE LENGTH: 24
25 SEQUENCE TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
30 MOLECULE TYPE: other nucleic acid (synthetic DNA)
SEQUENCE DESCRIPTION:
TCCTGGGCAG AGACCGGTTTC TCTA

35 SEQ ID NO: 16
SEQUENCE LENGTH: 10
SEQUENCE TYPE: amino acid
STRANDEDNESS: single
40 TOPOLOGY: linear
MOLECULE TYPE: N-terminal portion of protein
SEQUENCE DESCRIPTION:
50 Ala Arg Gly Ala Glu Arg Glu Xaa Glu Gly

1 5 10

55

Claims

1. A polypeptide derived from a mammal, which has erythroid burst-promoting activity or granulocyte macrophage colony-promoting activity on bone marrow cells of the mammal.
- 5 2. The polypeptide of claim 1, wherein the mammal is a human.
3. The polypeptide of claim 1, wherein the mammal is a mouse.
- 10 4. The polypeptide of claim 1, wherein the mammal is a rat.
- 5 5. The polypeptide of claim 2, which is a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 1, or a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 1 having substitution, deletion or addition of one or more amino acids and having erythroid burst-promoting activity or granulocyte macrophage colony-promoting activity.
- 15 6. The polypeptide of claim 5, which comprises the amino acid residues from position 22 to position 245 of the amino acid sequence shown in SEQ ID NO: 1.
- 20 7. The polypeptide of claim 2, which is a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 4, or a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 4 having substitution, deletion or addition of one or more amino acids and having erythroid burst-promoting activity or granulocyte macrophage colony-promoting activity.
- 25 8. The polypeptide of claim 3, which is a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 8, or a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 8 having substitution, deletion or addition of one or more amino acids and having erythroid burst-promoting activity or granulocyte macrophage colony-promoting activity.
- 30 9. The polypeptide of claim 4, which is a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 12, or a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 12 having substitution, deletion or addition of one or more amino acids and having erythroid burst-promoting activity or granulocyte macrophage colony-promoting activity.
- 35 10. A gene encoding the polypeptide of claim 5 or 6.
11. A gene encoding the polypeptide of claim 7.
12. A gene encoding the polypeptide of claim 8.
- 40 13. A gene encoding the polypeptide of claim 9.
14. The gene of claim 10, which has the nucleotide sequence shown in SEQ ID NO: 2.
- 45 15. The gene of claim 11, which has the nucleotide sequence shown in SEQ ID NO: 5.
16. The gene of claim 12, which has the nucleotide sequence shown in SEQ ID NO: 9.
17. The gene of claim 13, which has the nucleotide sequence shown in SEQ ID NO: 13.
- 50 18. *Escherichia coli* SHDM11610C (FERM BP-5849) into which the gene of claim 14 is transferred.
19. *Escherichia coli* HSCGF (FERM BP-5986) into which the gene of claim 15 is transferred.
- 55 20. *Escherichia coli* MSCGF (FERM BP-5987) into which the gene of claim 16 is transferred.
21. *Escherichia coli* RSCGF (FERM BP-6063) into which the gene of claim 17 is transferred.

22. A gene which hybridizes with a gene having the nucleotide sequence of claim 10 or 14 under stringent conditions and which encodes a polypeptide having erythroid burst-promoting activity or granulocyte macrophage colony-promoting activity.
- 5 23. A gene which hybridizes with a gene having the nucleotide sequence of claim 11 or 15 under stringent conditions and which encodes a polypeptide having erythroid burst-promoting activity or granulocyte macrophage colony-promoting activity.
- 10 24. A gene which hybridizes with a gene having the nucleotide sequence of claim 12 or 16 under stringent conditions and which encodes a polypeptide having erythroid burst-promoting activity or granulocyte macrophage colony-promoting activity.
- 15 25. A gene which hybridizes with a gene having the nucleotide sequence of claim 13 or 17 under stringent conditions and which encodes a polypeptide having erythroid burst-promoting activity or granulocyte macrophage colony-promoting activity.
- 20 26. A vector comprising the gene of any one of claims 10 to 25.
27. A transformant obtainable by introducing the vector of claim 26 into a host cell.
28. An antibody which reacts specifically with the polypeptide of claim 1.
29. A microorganism, an animal cell or an animal which produces the antibody of claim 28.
- 30 30. A method for producing the polypeptide of any one of claims 1 to 9, comprising culturing a cell carrying the gene of any one of claims 10-25 in a medium, producing and accumulating the polypeptide of claim 1, and recovering the polypeptide from the resultant culture.
31. A method for separating and purifying the polypeptide of any one of claims 1 to 9, comprising separating and purifying said polypeptide from the culture obtained by the method of claim 30 using one or more carriers selected from the group consisting of an anion exchange carrier, a hydrophobic exchange group, a gel filtration carrier, an affinity carrier having a color exchange group, a lectin affinity carrier and a metal-chelating carrier.
32. A pharmaceutical composition comprising the polypeptide of claim 1 as an active ingredient.
33. A λ phage vector which has a replication initiation region and a termination region both from a filamentous phage being present separately within the vector, and which has between said replication initiation region and said termination region at least 2 functional regions comprising a DNA region with a function to replicate a gene in *E. coli* and a DNA region with a function to express the gene in a mammalian cell.
34. The λ phage vector of claim 33, which is specified with λ SHDM.
35. The λ phage vector of claim 33, which is specified with λ CDM.
36. A method for isolating a gene using the λ phage vector of any one of claims 33 to 35.

50

55

FIG. 1

~~~~~AAAAA KB-M15 mRNA




FIG.2




FIG. 3




FIG.4




FIG.5




FIG.6




FIG.7




FIG.8




FIG.9




FIG.10




FIG.11




FIG.12




FIG. 13




FIG.14




FIG.15




FIG.16




FIG.17





FIG.18



| INTERNATIONAL SEARCH REPORT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                      | International application No.<br>PCT/JP97/02985 |           |                                                                                    |                       |      |                                                                                                                                                                                                                           |                   |   |                                                                                                                                                                                                                                      |        |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------|-----------|------------------------------------------------------------------------------------|-----------------------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|---|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
| <b>A. CLASSIFICATION OF SUBJECT MATTER</b><br>Int. Cl <sup>6</sup> C07K14/52, C07K16/24, C12N15/19, C12N1/21, C12N5/18, C12N5/20, C12P21/02, C12P21/08, A61K38/17<br>According to International Patent Classification (IPC) or to both national classification and IPC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                      |                                                 |           |                                                                                    |                       |      |                                                                                                                                                                                                                           |                   |   |                                                                                                                                                                                                                                      |        |
| <b>B. FIELDS SEARCHED</b><br>Minimum documentation searched (classification system followed by classification symbols)<br>Int. Cl <sup>6</sup> C07K14/52, C07K16/24, C12N15/19, C12N1/21, C12N5/18, C12N5/20, C12P21/02, C12P21/08, A61K38/17                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                      |                                                 |           |                                                                                    |                       |      |                                                                                                                                                                                                                           |                   |   |                                                                                                                                                                                                                                      |        |
| Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                      |                                                 |           |                                                                                    |                       |      |                                                                                                                                                                                                                           |                   |   |                                                                                                                                                                                                                                      |        |
| Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)<br>WPI (DIALOG), BIOSIS (DIALOG), CA (STN), GenBank/EMBL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                      |                                                 |           |                                                                                    |                       |      |                                                                                                                                                                                                                           |                   |   |                                                                                                                                                                                                                                      |        |
| <b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left; padding: 2px;">Category*</th> <th style="text-align: left; padding: 2px;">Citation of document, with indication, where appropriate, of the relevant passages</th> <th style="text-align: left; padding: 2px;">Relevant to claim No.</th> </tr> </thead> <tbody> <tr> <td style="padding: 2px;">P, X</td> <td style="padding: 2px;">HIRAOKA A. et al., "Cloning, expression, and characterization of a cDNA encoding a novel human growth factor for primitive hematopoietic progenitor cells", Proc. Natl. Acad. Sci. USA, Vol. 94 (July 1997), p. 7577-7582</td> <td style="padding: 2px;">1, 2, 5-27, 31-36</td> </tr> <tr> <td style="padding: 2px;">X</td> <td style="padding: 2px;">HIRAOKA A. et al., "Production of Human Hematopoietic Survival and Growth Factor by a Myeloid Leukemia Cell Line (KPB-M15) and Placenta as Detected by a Monoclonal Antibody", CANCER RESEARCH, Vol. 47 (Oct. 1, 1987), p. 5025-5030</td> <td style="padding: 2px;">1 - 36</td> </tr> </tbody> </table>                                                                                                                                          |                                                                                                                                                                                                                                      |                                                 | Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. | P, X | HIRAOKA A. et al., "Cloning, expression, and characterization of a cDNA encoding a novel human growth factor for primitive hematopoietic progenitor cells", Proc. Natl. Acad. Sci. USA, Vol. 94 (July 1997), p. 7577-7582 | 1, 2, 5-27, 31-36 | X | HIRAOKA A. et al., "Production of Human Hematopoietic Survival and Growth Factor by a Myeloid Leukemia Cell Line (KPB-M15) and Placenta as Detected by a Monoclonal Antibody", CANCER RESEARCH, Vol. 47 (Oct. 1, 1987), p. 5025-5030 | 1 - 36 |
| Category*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Citation of document, with indication, where appropriate, of the relevant passages                                                                                                                                                   | Relevant to claim No.                           |           |                                                                                    |                       |      |                                                                                                                                                                                                                           |                   |   |                                                                                                                                                                                                                                      |        |
| P, X                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | HIRAOKA A. et al., "Cloning, expression, and characterization of a cDNA encoding a novel human growth factor for primitive hematopoietic progenitor cells", Proc. Natl. Acad. Sci. USA, Vol. 94 (July 1997), p. 7577-7582            | 1, 2, 5-27, 31-36                               |           |                                                                                    |                       |      |                                                                                                                                                                                                                           |                   |   |                                                                                                                                                                                                                                      |        |
| X                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | HIRAOKA A. et al., "Production of Human Hematopoietic Survival and Growth Factor by a Myeloid Leukemia Cell Line (KPB-M15) and Placenta as Detected by a Monoclonal Antibody", CANCER RESEARCH, Vol. 47 (Oct. 1, 1987), p. 5025-5030 | 1 - 36                                          |           |                                                                                    |                       |      |                                                                                                                                                                                                                           |                   |   |                                                                                                                                                                                                                                      |        |
| <input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                      |                                                 |           |                                                                                    |                       |      |                                                                                                                                                                                                                           |                   |   |                                                                                                                                                                                                                                      |        |
| * Special categories of cited documents:<br>"A" document defining the general state of the art which is not considered to be of particular relevance<br>"E" earlier document but published on or after the international filing date<br>"L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)<br>"O" document referring to an oral disclosure, use, exhibition or other means<br>"P" document published prior to the international filing date but later than the priority date claimed<br>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention<br>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone<br>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art<br>"Z" document member of the same patent family |                                                                                                                                                                                                                                      |                                                 |           |                                                                                    |                       |      |                                                                                                                                                                                                                           |                   |   |                                                                                                                                                                                                                                      |        |
| Date of the actual completion of the international search<br>November 20, 1997 (20. 11. 97)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Date of mailing of the international search report<br>December 2, 1997 (02. 12. 97)                                                                                                                                                  |                                                 |           |                                                                                    |                       |      |                                                                                                                                                                                                                           |                   |   |                                                                                                                                                                                                                                      |        |
| Name and mailing address of the ISA/<br>Japanese Patent Office<br>Facsimile No.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Authorized officer<br>Telephone No.                                                                                                                                                                                                  |                                                 |           |                                                                                    |                       |      |                                                                                                                                                                                                                           |                   |   |                                                                                                                                                                                                                                      |        |

Form PCT/ISA/210 (second sheet) (July 1992)